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Herpes simplex virus (HSV) is a clinically important virus, whose life cycle 
alternates between productive replication and latency.  Infected cell protein 0 
(ICP0) is generally believed to play a key role in determining the outcome of HSV 
infections.  Synthesis of ICP0 promotes the productive replication of HSV, 
whereas absence of ICP0 renders HSV prone to establish latent infections.   
In the first part of the dissertation, I attempt to address the question how is 
ICP0 gene regulated.  To tackle this question, we constructed recombinant HSV 
that encodes GFP-tagged ICP0 so that the regulation of ICP0 gene can be 
visualized in real time.  Using this reagent, we found that ICP0 gene was subject 
to potent repression immediately following infection.  Surprisingly, HSV’s major 
transcriptional regulator, ICP4, was necessary and sufficient to repress ICP0 
gene, and did so in an ICP4-binding-site dependent manner.  Synthesis of ICP0 
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alleviated the ICP4-dependent repression of ICP0 gene.  ICP4 co-
immunoprecipitated with FLAG-tagged ICP0, thus, a physical interaction between 
ICP0 and ICP4 likely explains how ICP0 antagonizes ICP4’s capacity to silence 
the ICP0 gene.  Therefore, our findings suggest that ICP0 gene is differentially 
regulated by virus-encoded repressor ICP4 and virus-encoded antirepressor 
ICP0. 
In the second part of the dissertation, I attempt to address the question 
what function does ICP0 assume.  Since the discovery of ICP0, the nuclear 
function of ICP0 has been the focal point of studies, whereas the cytoplasmic 
function of ICP0 is unknown.  While pursuing our first study, we unexpectedly 
found that GFP-tagged ICP0 was predominantly localized to the cytoplasm 
during infections.  Taking advantage of live-cell imaging, we found that ICP0 
translocated from nucleus to cytoplasm during early phase of HSV infections, 
where it bundled and dispersed microtubules.  Synthesis of ICP0 was proved to 
be necessary and sufficient to dismantle microtubules in HSV-infected and 
transfected cells.  Therefore, our findings suggest ICP0 might play a previously 
unrecognized role in the cytoplasm through dismantling microtubule networks of 
the host cells.  Furthermore, our study represents the first report showing a virus-
encoded E3 ligase disrupts host cell microtubule networks, thus suggests a 
general function of many other viral E3 ligases. 
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CHAPTER1: INTRODUCTION 
 
Herpes simplex virus (HSV) infection is a clinically important virus, which is 
carried by 80% of the population in the world (1).  Although there is only 2% 
chance that a given HSV infection will progress into recurrent herpetic diseases, 
the actual number of people suffering from herpetic disease is estimated to be 
100 million due to the high prevalence of HSV (1).   
HSV life cycle alternates between productive replication and latency.  
Although the mechanisms by which HSV establishes, maintains and reactivates 
from latency are not well understood,  it is generally believed that ICP0 plays an 
important role in the regulation of the balance between productive and latent 
infections (2, 3).  Synthesis of ICP0 tips the balance toward productive infection, 
whereas absence of ICP0 tilts the balance toward latent infection (2, 3).  
Therefore, it would be of extreme interest to understand the questions 1) how is 
ICP0 gene regulated, and 2) what function does ICP0 assume during HSV 
infection.  The specific introduction to each question is detailed below: 
 
1.1. GENE REGULATION OF ICP0 
During productive replication, ~75 proteins are synthesized from the herpes 
simplex virus (HSV) genome in a temporal cascade (4).  Virion protein 16 (VP16) 
in the tegument of HSV virions forms a complex with the cellular transcription 
factor Oct 1 to initiate a cascade of viral gene expression (5, 6).  Only five 
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immediate-early (IE) genes are initially induced based on the presence of VP16-
responsive elements in their promoters (7).  Viral IE proteins such as infected cell 
proteins 0 (ICP0) and 4 (ICP4) are believed to play a key role in activating viral 
mRNA synthesis, and thus promoting the synthesis of ~70 early (E) and late (L) 
proteins that replicate and package HSV genomes into new virions. 
ICP0 was first identified based on its capacity to transform HSV’s major 
transcriptional regulator, ICP4, from a weak transcriptional activator to a potent 
activator of mRNA synthesis; specifically, combinations of ICP0 and ICP4 are 20-
fold more potent at driving mRNA synthesis than either ICP0 or ICP4 alone (8, 
9).  Functionally, synthesis of ICP0 causes HSV’s equilibrium to abruptly tip 
towards productive replication, whereas absence of ICP0 produces the opposite 
effect.  Synthesis of ICP0 is sufficient to trigger HSV reactivation in trigeminal 
ganglion neurons and other models of latent HSV infection (10, 11).  HSV ICP0- 
viruses replicate to nearly wild-type levels when cells are inoculated with more 
than 1 plaque-forming unit (pfu) of virus per cell.  At multiplicities of infection 
(MOI) below 0.1 pfu per cell, the same ICP0- viruses establish quiescent 
infections in 99% of the cells they infect (12, 13).  Such observations suggest that 
ICP0 antagonizes a repressor of HSV replication, whose repressive capacity can 
be saturated with high numbers of HSV genomes (13). 
Preston and Everett first articulated the concept of an ICP0-antagonized 
repressor of HSV gene expression (3, 14).  Because ICP0 is an E3 ubiquitin 
ligase (15), it was suggested that a repressor might silence HSV mRNA 
synthesis in the absence of ICP0, whereas synthesis of ICP0 would result in 
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ubiquitination and/or proteasomal destruction of the repressor, thus allowing HSV 
mRNA synthesis to proceed unhindered (16).  Since the advancement of this 
hypothesis, many laboratories have joined in the search for the unidentified 
repressor(s) of HSV gene expression.  Individual cellular proteins that co-localize 
with ICP0 have been probed for their capacity to function as repressors of HSV 
replication such as PML and Sp100 (17, 18). Suspected pathways of silencing 
HSV genomes, such as epigenetic silencing, have been explored to determine if 
HSV ICP0- null viruses are more sensitive to these gene silencing mechanisms 
(19-22).  Based on such inquiries, the list of proteins that may function as ICP0-
antagonized repressors of HSV gene expression continues to grow and currently 
includes PML (17-19, 23), Sp100 (24), cyclin D3 (25), IRF-3 and IRF-7 (26), 
centromeric proteins CENP-B and CENP-C (27, 28), HDAC1/2-CoREST-REST 
(19), DNA-dependent protein kinase (29), and class II histone deacetylases (22). 
The PML protein is among the most carefully scrutinized of the potential 
ICP0-antagonized repressors of HSV replication.  In support of the PML 
repressor hypothesis, ICP0 and HSV genomes co-localize with PML nuclear 
bodies in cells (30, 31), synthesis of ICP0 triggers the dispersal of PML nuclear 
bodies (30), and PML is strongly induced by interferon treatments that are known 
to impede HSV replication (32).  Weaknesses in the PML repressor hypothesis 
include the fact that overexpression of PML does not inhibit HSV gene 
expression and does not interfere with the replication of wild-type HSV or ICP0- 
null viruses (33); unpublished data of W. Halford].  Although siRNA-knockdown of 
both PML and Sp100 results in an ~40-fold increase in the replication of HSV 
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ICP0- null viruses in human fibroblasts, this represents less than a 1% 
complementation of the >10,000-fold repression that occurs in these cells (18).  
Finally, there is no direct evidence of a physical interaction between ICP0 and 
PML (34). 
Like many laboratories, we too have been interested in understanding why 
failure to synthesize ICP0 results in limited mRNA transcription from the HSV 
genome.  Rather than interrogate specific proteins for their capacity to repress 
viral mRNA synthesis, we chose to establish an experimental system that would 
allow us to rapidly monitor repression of a single HSV IE gene, the ICP0 gene.   
To this end, an ICP0- virus was constructed that bore an ~750 bp insertion of 
green fluorescent protein (GFP) coding sequence and a stop codon in exon 2 of 
the ICP0 gene.  The resulting virus, HSV-1 0-GFP, synthesized a 3.5 kb ICP0-GFP 
mRNA and a truncated ICP0-GFP peptide.  Using the GFP fluorescent reporter as 
a screening tool, we probed for conditions that alleviated or exacerbated 
repression of the ICP0-GFP reporter gene in HSV-infected cells such as presence 
or absence of biologically active ICP0. 
With the aid of these new reagents, we report the identification of a protein 
that satisfied four empirical criteria that should be expected of an ICP0-
antagonized repressor of HSV mRNA transcription; specifically, the identified 
protein 1. was required to observe repression of ICP0 mRNA synthesis in HSV-
infected cells; 2. was sufficient to repress ICP0 mRNA synthesis in the absence 
of ICP0; 3. was unable to silence ICP0 mRNA synthesis when ICP0 
accumulated; and 4. physically interacted with ICP0. 
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We report the unexpected finding that the viral IE protein, ICP4, satisfied all 
of the criteria expected of a bona fide ICP0-antagonized repressor of HSV mRNA 
transcription.  It is relevant to note that ICP4’s capacity to function as a repressor 
of HSV IE mRNA transcription is well established, particularly in the context of 
the ICP4 and L/ST genes (35, 36).  Evidence has been presented both for and 
against the hypothesis that ICP4 represses the ICP0 gene in HSV-infected cells 
(37, 38).  However, the perceived importance of the hypothesis may be 
measured in terms of the attention it has received; 14 years have elapsed since 
the last published study that considered ICP4’s potential to repress the ICP0 
gene (38). 
We present new evidence that corroborates earlier findings that ICP4’s 
capacity to repress ICP0 mRNA synthesis is indeed modest when ICP0 
accumulates.  However, when ICP0 fails to accumulate, then ICP4 is capable of 
silencing the ICP0 gene.  We present functional evidence that ICP0 antagonizes 
ICP4-dependent repression of the ICP0 gene.  In addition, we present the first 
direct evidence that ICP0 and ICP4 physically interact in HSV-infected cells.  
Collectively, these data suggest an alternative view of HSV gene regulation, 
which is consistent with the biology of a virus that establishes latent infections:  In 
the absence of ICP0, ICP4 functions as an efficient repressor of HSV IE mRNA 
transcription, whereas accumulation of ICP4’s binding partner, ICP0, converts 
ICP4 from a repressor to an activator of HSV mRNA synthesis (8, 9).   The 
findings that led us to these unexpected conclusions are presented below. 
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1.2. FUNCTION OF ICP0  
ICP0’s mechanism of action is unknown, but the possibilities are 
constrained by four facts:  1. ICP0 potentiates ICP4’s function as a transcriptional 
activator of HSV mRNA synthesis (8, 9, 39); 2. ICP0 is a RING-finger E3 
ubiquitin ligase (15, 40); 3. ICP0 is essential for HSV’s resistance to the innate 
interferon response of animals (2, 41); and 4. ICP0’s E3 ubiquitin ligase activity 
triggers the dispersal of pro-myelocytic leukemia (PML) nuclear bodies (30, 42), 
which may contribute to the formation of adjacent, sub-nuclear replication 
compartments (43, 44). 
Point mutations in ICP0’s RING-finger domain (amino acids 116 to 156) 
destroy ICP0’s E3 ligase activity and destroy ICP0’s capacity to promote HSV 
replication (40).  It remains unclear which substrate(s) explain how ICP0’s E3 
ligase activity promotes HSV replication and spread.  Although ICP0 triggers the 
efficient dispersal of PML nuclear bodies, ICP0 does not ubiquitinate the PML 
protein in an in vitro E3 ligase assay (45). 
In the first part of the dissertation, we clarifies that ICP0 physically interacts 
with HSV’s major transcriptional regulator, ICP4, and suggests that ICP0 
influences whether ICP4 functions predominantly as an activator or a repressor 
of HSV mRNA synthesis (39).  However, ICP0’s interaction with ICP4 does not 
explain 1. how ICP0 triggers the dispersal of PML nuclear bodies and centromere 
proteins (27, 42), nor does it explain 2. why synthesis of ICP0 causes cells to 
arrest in the G2/M phase of the cell cycle (46, 47).  These latter observations 
suggest that ICP0 must interact with at least one cellular protein.  Rather than 
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interrogate specific proteins for their capacity to interact with ICP0, we chose to 
use live-cell imaging to determine if new clues might be obtained by tracking the 
distribution of a green fluorescent protein (GFP)-tagged form of ICP0 in HSV-
infected cells over time. 
Three ICP0+ viruses were constructed that bore an ~750 bp insertion of 
GFP coding sequence inserted in the ICP0 gene.  The resulting recombinant 
viruses, HSV-1 0+GFP12, HSV-1 0+GFP24, and HSV-1 0+GFP105 each 
synthesized a 3.5 kb ICP0+GFP mRNA and a 140 kDa protein.  Each GFP-tagged 
ICP0 protein retained much of ICP0’s activity, and was visible in HSV-1 infected 
cells by fluorescent microscopy.  Contrary to our initial expectations, the majority 
of GFP-tagged ICP0 was observed in the cytoplasm of HSV-1 infected cells.  
Subsequent tests verified that wild-type ICP0 also accumulated to much higher 
levels in the cytoplasm than in the nucleus of virus-infected cells. 
Since the discovery that ICP0 potently stimulates HSV mRNA synthesis (8, 
9), sporadic reports have documented the presence of ICP0 in the cytoplasm of 
HSV-infected cells, or have described ICP0 translocating from the nucleus to the 
cytoplasm of HSV-infected cells (48-52).  The biological significance of 
cytoplasmic ICP0 remains obscure, and it remains possible that cytoplasmic 
ICP0 represents an artifact of ICP0 overexpression (48, 49).  Therefore, ICP0 
continues to be discussed predominantly in terms of its potential function(s) in 
the nucleus of HSV-infected cells (17, 27, 53, 54). 
The results of the current study clarify that ICP0 is an exclusively nuclear 
protein during the IE phase of HSV infection, but translocates to the cytoplasm 
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during the early (E) phase.  Once in the cytoplasm of HSV-infected cells, ICP0 
efficiently bundles and disperses host cell microtubules.  Microtubule networks 
are known to be disrupted in HSV-infected cells (55), but the effectors that 
mediate this process are unknown.  The HSV-1 tegument protein VP22 bundles 
microtubules when overexpressed in transfected cells (56), but this is not 
observed in HSV-infected cells (57).  Our results demonstrate that ICP0 is 
necessary and sufficient to trigger the complete disassembly of the host cell 
microtubule network.  This finding adds to a growing list of proteins encoded by 
plant and animal viruses that reorganize microtubules (58-61).  
This is the first report of a viral E3 ligase that regulates microtubule stability.  
Intriguingly, cellular E3 ligases such as the anaphase-promoting complex and 
cullin 3 orchestrate massive reorganizations of microtubules during mitosis (62-
64).  ICP0-like E3 ligases are not unique to herpes simplex virus, but are 
encoded by at least 20 other α-herpesviruses that infect primates, dogs, pigs, 
frogs, fish, and other species (65, 66).  Thus, our results raise the possibility that 
an ancestral herpesvirus may have stolen an E3 ligase from its host cell, and 
modified this regulator of microtubule stability to suit the needs of the virus.  
Specifically, our results imply that ICP0 possesses a mitosis-related regulatory 
activity that disassembles microtubules upon ICP0’s translocation to the 
cytoplasm, and hence prepares the host cell for the synthesis and/or egress of 
newly formed HSV virions. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1. CELLS AND VIRUSES 
Vero cells and 293 cells were obtained from the American Type Culture 
Collection (Manassas, VA).  ICP4-complementing E5 and ICP0-complementing 
L7 cell lines were kindly provided by Neal Deluca (University of Pittsburgh; (67)).  
ICP27-complementing V27 cells and HSV-1 d27-1 (ICP27-) virus were a kind gift 
of Steve Rice (University of Minnesota Medical School, Minneapolis; Ref. (68)).  
Cell lines were propagated in Dulbecco’s Modified Eagle’s medium (DMEM) 
supplemented with 5% fetal bovine serum and antibiotics.  
Table 1 summarizes the HSV-1 recombinant viruses used in this study, 
which are derivative of low passage strains of wild-type HSV-1 strain KOS (69).  
HSV-1 KOS, HSV-1 22/n199 (ICP22-; Ref. (70)), HSV-1 0+GFP12 (ICP0+GFP-12), 
HSV-1 0+GFP24 (ICP0+GFP-24), HSV-1 0+GFP105 (ICP0+GFP-105) and HSV-1 0+4BS- 
(ICP0+GFP-105) were propagated in Vero cells.  The HSV-1 ICP4- virus n12 (71) 
and the ICP4 temperature-sensitive virus HSV-1 tsB21 (72) were propagated in 
ICP4-complementing E5 cells.  The HSV-1 ICP0- viruses n212 (73), 0-GFP 
(ICP0-GFP), 0-4BS- (ICP0-GFP) and 0(∆RING) (ICP0∆RING) were propagated and 
titered in ICP0-complementing L7 cells, as was the HSV-1 VP16- virus RP4 (74) 
that was kindly provided by Steve Triezenberg (Michigan State University, East 
Lansing). 
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HSV-1 strain KOS was used as the parental wild-type virus in this study.  
KOS and all of the HSV-1 recombinant viruses used in this study were 
propagated in Vero cells, L7 cells, or E5 cells cultured in complete DMEM.  KOS-
GFP is a recombinant virus derived from HSV-1 strain KOS that expresses GFP 
from a CMV promoter cassette inserted in the intergenic region at the 3' ends of 
the UL26 and UL27 genes (75, 76).  To construct HSV-1 recombinant viruses, a 
7.3 kb DNA fragment which encompasses the entire LAT-ICP0 locus was first 
subcloned from HSV-1 strain KOS into a pCRII plasmid vector (Invitrogen 
Corporation, Carlsbad, CA).  Mutations were introduced into the ICP0 gene of 
this plasmid, as described below. 
i. p0+GFP12:  A GFP coding sequence was amplified from plasmid 
peGFP-N1 (Clontech Laboratories, Mountain View, CA) using PCR primers that 
added NcoI and Bsu36I restriction sites to the 5’ and 3’ ends of the GFP coding 
sequence.  Following PCR amplification with a high fidelity mixture of 
thermostable DNA polymerases, the GFP sequence was subcloned into NcoI 
and Bsu36I sites that occur in codons 1 and 11 of the ICP0 coding sequence.  
The resulting plasmid, p0+GFP12, encoded ICP0+GFP-12 protein.  The genetic 
identity of this and all GFP insertions in the ICP0 gene was confirmed by DNA 
sequencing.  Homologous recombination between HSV-1 KOS and the p0+GFP12 
plasmid yielded the recombinant virus HSV-1 0+GFP12. 
ii. p0+GFP24:  The plasmid p0+GFP24 was created by PCR amplification of 
three DNA fragments that were ligated in series to create a GFP insertion at the 
5’ end of exon 2 of the ICP0 gene (Fig. 1A).  Specifically, 1. the 3’ end of intron 1 
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of the ICP0 gene; 2. a GFP coding sequence; and 3. the 5’ half of exon 2 of the 
ICP0 gene were PCR-amplified, ligated together, sequenced, and the resulting 
BamHI - XhoI fragment was subcloned into the BamHI - XhoI sites in the ICP0 
gene.  The resulting plasmid, p0+GFP24, encoded ICP0+GFP-24 protein in which 
GFP is inserted between amino acids 23 and 24 of ICP0.  Homologous 
recombination between HSV-1 KOS and the p0+GFP24 plasmid yielded the 
recombinant virus HSV-1 0+GFP24. 
iii. p0-GFP: The plasmid p0-GFP gene was created by inserting a 
polylinker, GFP coding sequence, and stop codon derived from the plasmid 
peGFP-N1 (Clontech Laboratories) into a XhoI site in codon 104 of the ICP0 
gene.  The resulting plasmid, p0-GFP, encoded the N-terminal 104 amino acids 
of ICP0, a 14 amino acid linker, and GFP.  Homologous recombination between 
HSV-1 KOS and the p0-GFP plasmid yielded the recombinant virus HSV-1 0-
GFP.   
iv. p0+GFP105: The plasmid p0+GFP105 was derived by subcloning a 
dsDNA linker containing BsrGI and XhoI sites (tgtaca agatat ctcgag) in the 3’ end 
of the GFP coding sequence in p0-GFP.  Thus, a TAA terminator codon was 
removed and the GFP and ICP0 coding sequences were placed in the same 
open-reading frame.  The resulting plasmid, p0+GFP105, encoded ICP0+GFP-105 
protein in which GFP is inserted between amino acids 104 and 105 of ICP0.  
Homologous recombination between HSV-1 KOS and p0+GFP105 yielded the 
virus HSV-1 0+GFP105. 
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v. p0∆RING: The plasmid p0∆RING was derived by deletion of codons 
105-229 of the ICP0 gene from p0+GFP105.  Homologous recombination between 
HSV-1 KOS and the p0∆RING plasmid yielded the recombinant virus HSV-1 
0∆RING. 
vi. p0-4BS- and p0+4BS-: The plasmids p0-4BS- and p0+4BS- were 
created as follows.  A plasmid, pmin0-GFP, contains the ICP0 promoter region 
and a unique TfiI restriction site that overlaps the ICP4 DNA-binding site (4BS) 
element in the ICP0 promoter.  Thus, mutation of the 4BS element was achieved 
by linearizing pmin0-GFP with TfiI, using mung bean exonuclease to remove 
ssDNA overhangs, and religating with T4 DNA ligase.  The 4-bp deletion in the 
4BS element was confirmed by the loss of the TfiI restriction site and DNA 
sequencing (Figure 1A).  The ICP4-binding site mutation was transferred into the 
larger plasmids p0-GFP and p0+GFP105 by subcloning a XhoI - EcoRI restriction 
fragment to yield the plasmids p0-4BS- and p0+4BS-.  Homologous recombination 
between HSV-1 KOS and these plasmids yielded the HSV-1 recombinant viruses 
0-4BS- and 0+4BS- (Table 1). 
vii. p0+FLAG24: The plasmid p0+FLAG24 was created as follows.  A 
plasmid, p0+GFP24, contained a BglII restriction site-GFP coding sequence-SpeI 
restriction site insertion between amino acids 23 and 24 of the ICP0 open-
reading frame.  A dsDNA oligonucleotide linker of the following sequence was 
synthesized, CCCAGATCTGGACTACAAGGACGATGACGACAAACTAGTCTG, 
digested with BglII and SpeI, and subcloned in place of the GFP sequence to 
create p0+FLAG24. The resulting gene encoded a FLAG-tagged protein that bore 
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the amino acid sequence LDYKDDDDKL between amino acids 23 and 24 of 
ICP0.  Homologous recombination between HSV-1 KOS and p0+FLAG24 yielded 
the HSV-1 recombinant virus 0+FLAG24 (Table 1). 
Table 2 summarizes the ΔE1-ΔE3 adenovirus vectors used in this study, 
which were propagated in human embryonic kidney 293 cells in complete DMEM, 
as described previously (10).  Adenovirus titers were determined by a limiting 
dilution analysis in 96-well cultures of 293 cells to establish the titer of infectious 
virus in terms of 50% tissue-culture infectious dose (TCID50).  One TCID50 unit is 
equivalent to 1 pfu, but the TCID50 assay is less prone to underestimate 
adenovirus vector titers (unpublished data). 
 
2.2. CONSTRUCTION OF RECOMBINANT HSV-1 VIRUSES 
Infectious HSV-1 DNA was prepared by a protocol that relies upon dialysis 
to minimize shearing of genome-length HSV-1 DNA; this is a modification of a 
protocol that was generously provided by Karen Mossman (McMaster University, 
Hamilton, Ontario).  Five 100 mm dishes of Vero cells (3x107 cells) were 
inoculated with 5 pfu per cell of HSV-1 strain KOS.  After 24 hours, cells were 
scraped, centrifuged, rinsed with PBS, resuspended in 7.0 ml of 200 mM EDTA 
pH 8.0, and transferred into a 15 ml conical.  Proteinase K (75 µl of 10 mg/ml) 
and 375 µl of 10% SDS were added to virus-infected cells, and the tube was 
incubated in a rotisserie oven with slow rotation at 50ºC for 16 hours.  Proteins 
were removed by phenol : chloroform extraction, and DNA was transferred into a 
0.5 – 3.0 mL Slide-a-lyzer cassette (10,000 MW cutoff; Pierce Chemical Co., 
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Rockford, IL) and dialyzed against 0.1x standard saline citrate for 24 hours.  
Following dialysis, infectious HSV-1 DNA was aliquoted and frozen at -80ºC. 
Recombinant HSV-1 viruses were generated by co-transfection of 2 µg 
infectious HSV-1 KOS DNA and 1 µg each plasmid into a 60 mm dish containing 
8 x 105 ICP0-complementing L7 cells.  After 12 hours, medium was replaced with 
complete DMEM containing 1% methylcellulose and GFP+ plaques were selected 
on a Nikon TE2000 fluorescent microscope (Nikon Instruments, Lewisville, TX).  
GFP+ recombinant viruses were repeatedly passed in ICP0-complementing L7 
cells until a uniform population of viruses was obtained that produced 100% 
GFP+ plaques, at which time Southern blot analysis was used to confirm that the 
anticipated mutation had been introduced into the ICP0 gene of HSV-1. 
 
2.3. SOUTHERN BLOT ANALYSIS 
Vero cell cultures were established at a density of 1.5 x 106 cells per 100 
mm dish and were inoculated with viruses at an MOI of 5 pfu per cell.  DNA was 
harvested from virus-infected cells or uninfected controls at 24 hours p.i. using a 
standard DNA extraction procedure and Southern blot analysis was performed as 
previously described (77, 78).  Oligonucleotide probes specific for intron 1 of the 
ICP0 gene (5’-cccctagatgcgtgtgagtaaggggggcctgcgtatgagt-3’) were used to 
probe restriction fragments of HSV-1 viruses.   
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2.4. NORTHERN BLOT ANALYSIS 
Cultures of L7 or Vero cells were established at a density of 1.5 x 106 cells 
per plate in 60 mm dishes, and inoculated with MOIs of 0.1 to 5 pfu per cell.  
RNA was isolated using Ultraspec RNA isolation reagent (Biotecx Inc., Houston, 
TX).  Equal amounts of total RNA (10 μg) were electrophoretically separated on 
1% formaldehyde agarose gels, blotted onto Zeta Probe GT nylon membranes 
(Biorad Laboratories, Hercules, CA), and hybridized with radiolabeled  
oligonucleotides specific for exon 3 of HSV-1 ICP0 mRNA (5'-ggagtcgctgatc-
actatggggtctctgttgtttgcaagg-3'), GFP mRNA (5’-atagacgttgtggctgttgtagttgt-
actccagcttgtgc-3′), HSV-1 glycoprotein D mRNA (5'-aggcccccagagacttgtt-
gtaggagcattcggtgtactc-3') or cellular GAPDH mRNA (5'-tgaccttggccaggggtgctaa-
gcagttggtggtgcagga-3').  Oligonucleotides were end-labeled with [α-32P] dATP 
using terminal deoxynucleotidyl transferase (Promega Corporation, Madison, WI) 
and were hybridized to their target sequence via 16 hours of hybridization at 
37°C in a solution containing 5 ng/ml labeled probe, 7% SDS, 120mM NaH2PO4, 
and 250mM NaCl.  Excess probe was removed from membranes by sequential 
rinses in 0.1x standard saline citrate containing 0.1% SDS.  Blots were exposed 
to phosphor screens, which were scanned and analyzed with a Cyclone 
PhosphorImager and OptiQuant software (Perkin Elmer, Boston, MA). 
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2.5. WESTERN BLOT ANALYSIS  
Vero cell cultures were established at a density of 3 x 105 cells per well in 
12-well plates, and were infected at an MOI of 10 pfu per cell.  After 18 hours, 
proteins were harvested using mammalian protein extraction reagent (Pierce 
Chemical Co., Rockford, IL) supplemented with 1 mM dithiothreitol and protease 
inhibitor cocktail set I (Calbiochem, La Jolla, CA).  After heat denaturation, 20 μg 
of each protein sample and MagicMarkTM XP protein MW markers (Invitrogen 
Corporation, Carlsbad, CA) were resolved in a 10% polyacrylamide gel with a 4 
% stacking gel, and were transferred to nitrocellulose membranes.  Protein blots 
were blocked in phosphate-buffered saline  (PBS) containing 5% nonfat dry milk, 
and were incubated overnight at 4°C  in PBS + 0.1% Tween-20 + 5% nonfat dry 
milk containing a  1:1000 dilution of mouse monoclonal H1083 antibody specific 
for amino acids 395 to 775 of ICP0 (79-81) (EastCoast Bio, North Berwick, MA) 
and a 1:500 dilution of rabbit polyclonal anti-GFP antibody (Clontech 
Laboratories Inc.).  Following incubation with primary antibodies, membranes 
were washed four times with PBS + 0.1% Tween-20 (PBS-T), and were 
incubated for 1 hour with 1:20,000 dilution of goat anti-rabbit IgG and goat anti-
mouse IgG conjugated, respectively, to the infrared fluorescent dyes IRDye® 680 
and IRDye® 800CW (LI-COR Bioscience, Lincoln, NE).  Protein blots were 
washed three times in PBS-T, and were scanned for two-color fluorescence 
using the Odyssey Infrared imaging system (LI-COR Bioscience). Data were 
analyzed using Odyssey application software version 3.0.16 (LI-COR 
Bioscience). 
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2.6. IMMUNOFLUORESCENT STAINING IN VERO CELLS 
Immunofluorescent staining in Vero cells was performed using an 
adaptation of a staining protocol that was generously provided by Roger Everett 
(MRC Virology Unit, Glasgow, Scotland).  Glass coverslips were placed on the 
bottom of 6-well dishes and Vero cells were seeded at a density of 1 x 106 cells 
per well.  After allowing 8 hours for cell attachment, cultures were inoculated with 
HSV-1 viruses using the conditions defined in each Figure Legend and Results 
sub-section.  At the indicated time of harvest, glass coverslips were removed 
from culture wells, and were fixed with PBS containing 3% formaldehyde and 2% 
sucrose for 10 minutes, followed by permeabilization with 90% methanol for 10 
minutes.  HSV-1 Fc-γ receptors (glycoprotein E-I heterodimers; Ref. (82)) were 
blocked along with all other non-specific protein-binding sites by incubating fixed 
cells in a solution of PBS containing 0.5% fetal bovine serum (FBS), as well as 
10 µg / ml each of the γ-globulin fractions of human, donkey, and goat serum 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).  Fixed cells 
were incubated in PBS + FBS + γ-globulin block solution for 10 minutes, and the 
same solution was used as the diluent for primary and secondary antibodies.  
Each protein of interest was labeled by incubating fixed cells in a 1:1000 dilution 
of primary antibody for 16 hours.  Excess primary antibody was removed by 
washing with PBS + FBS + γ-globulin block solution, and cells were then 
incubated for 1 hour in PBS + FBS + γ-globulin block containing a 1:1000 dilution 
of each secondary antibody as well as 10 ng / ml of Hoechst 33342 (Calbiochem, 
La Jolla, CA).  Excess secondary antibody was removed by washing with the 
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PBS + FBS + γ-globulin block solution, and coverslips were mounted on glass 
slides using FluorSave Reagent (Calbiochem, Gibbstown, NJ).  Cells on 
coverslips were photographed using an Olympus BX41 microscope equipped 
with Olympus DP70 digital camera (Olympus America, Center Valley, PA).  
Images of green, red, and blue fluorescence were captured at exposure times of 
500, 200, and 20 ms, respectively.  
The primary antibodies were mouse α-ICP0 monoclonal antibody H1083 
(EastCoast Bio), mouse anti-FLAG monoclonal antibody (Sigma Chemical Co.), 
rabbit anti-α-tubulin polyclonal antibody ab18251 (Abcam, Cambridge, MA), 
rabbit anti-β-COP polyclonal antibody ab2899 (Abcam, Cambridge, MA), rabbit 
anti-calreticulin polyclonal antibody ab4 (Abcam, Cambridge, MA).  The 
secondary antibodies were Alexa Fluor 594-conjugated goat α-mouse IgG 
(Molecular Probes, Eugene, OR), fluorescein-conjugated goat α-mouse IgG 
(Jackson ImmunoResearch), or DyLight 594-conjugated donkey α-rabbit IgG 
(Jackson ImmunoResearch). 
 
2.7. CO-IMMUNOPRECIPITATION  
Replicate 100 mm dishes containing 107 Vero cells were inoculated with 
vehicle or 5 pfu per cell of HSV-1 KOS or HSV-1 0+FLAG24 in the presence of 
200 µM cycloheximide.  At 10 hours p.i., cycloheximide-containing medium was 
replaced with 10 µg/ml actinomycin D, and 6 hours was allowed for translation of 
accumulated IE mRNAs.  At 16 hours p.i., 100 mm dishes of Vero cells were 
washed with ice-cold phosphate-buffered saline, and cells were lysed in either 
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0.5 ml of an NP40-based buffer or RIPA buffer.  The NP40-based buffer 
contained 50 mM Tris (pH 7.4), 150 mM sodium chloride, 2 mM EDTA, 1% 
NP40, and 1x Halt protease inhibitor cocktail (Pierce Chemical Co.).  RIPA buffer 
consisted of 50 mM Tris (pH 8.0), 150 mM sodium chloride, 1% NP40, 0.5% 
sodium deoxycholate, 0.1% SDS, and 1x Halt protease inhibitor cocktail.  Cell 
lysed for 2 hours at 4ºC on a rotisserie, cell debris was removed by 
centrifugation, and 10% of each lysate was reserved for Western blot comparison 
of relative levels of ICP0 and ICP4.  Supernatants were pre-cleared by incubation 
with 1 μg normal mouse IgG and Protein A/G agarose beads (SantaCruz 
Biotechnology) for 30 min at 4ºC.  Pre-cleared supernatants were incubated with 
15 μl of FLAG-M2 agarose beads (Sigma Chemical Company) overnight at 4ºC.  
Immunocomplexes were washed four times with NP-40 buffer containing 500 mM 
NaCl or RIPA buffer, and were prepared for Western blot analysis by boiling in 2x 
Laemmli loading buffer prior to electrophoresis on an 8% polyacrylamide gel.   
Transfer and detection of blotted proteins on PVDF membranes was performed 
as described above. 
 
2.8. TRANSFECTION OF VERO CELLS 
Vero cells were transfected with plasmid DNA (0.75μg / well in 12-well 
plates) using Lipofectamine 2000 (Invitrogen Corporation, Carlsbad, CA) in 
complete DMEM at 37°C.  Medium was replaced at 4 hours post-transfection to 
avoid toxicity associated with the transfection reagent, and cells were incubated 
at 37°C in complete DMEM until cells were fixed for immunofluorescent staining. 
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Table 1 
                                        Description of HSV-1 viruses 
Virus / 
Genotype 
Phenotype / Properties Reference 
KOS (wild-
type) 
Wild-type laboratory strain of HSV-1 (12 passages removed from isolation). (69) 
n212 (ICP0- 
null) 
Replicates with 1% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes the first 
211 of 775 amino acids of ICP0. 
(73) 
0-GFP 
(ICP0- null) 
Replicates with 1% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes the first 
104 amino acids of ICP0 coupled to GFP. 
this study 
0-4BS- 
(ICP0- null) 
Replicates with 1% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes the first 
104 amino acids of ICP0 coupled to GFP.  A 4-bp deletion disrupts the ICP4 DNA-
binding site in the ICP0 promoter. 
this study 
0+GFP12 
(ICP0+) 
Replicates with 66% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes full-
length ICP0 with GFP in lieu of the first 11 amino acids. 
this study 
0+GFP24 
(ICP0+) 
Replicates with 66% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes full-
length ICP0 with GFP inserted between amino acids 23 and 24. 
this study 
0+GFP105 
(ICP0+) 
Replicates with 66% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes full-
length ICP0 with GFP inserted between amino acids 104 and 105. 
this study 
0∆RING 
(ICP0- null) 
Replicates with 1% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes ICP0 
with GFP in lieu of amino acids 105 and 229. 
this study 
0+4BS- 
(ICP0+) 
Replicates with 66% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes full-
length ICP0 with GFP inserted between amino acids 104 and 105.  A 4-bp deletion 
disrupts the ICP4 DNA-binding site in the ICP0 promoter. 
this study 
0+FLAG24 
(ICP0+) 
Replicates with 100% efficiency at MOIs below 0.1 pfu per cell; virus synthesizes full-
length ICP0 with FLAG epitope inserted between amino acids 23 and 24. 
this study 
RP4 (VP16- 
null) 
Replicates with 1% efficiency at MOIs <0.1 pfu per cell; virus synthesizes VP16 protein 
lacking half of the acidic transactivation domain (Δa.a. 413-454 [of 490]). (74) 
n12 (ICP4- 
null) 
Incapable of replication unless ICP4 is provided in trans; virus synthesizes the first 252 
of 1298 amino acids of ICP4. 
(83) 
tsB21 
(ICP4ts) 
Replication-competent at 34º; replication-defective at 39.5º C; virus synthesizes a 
temperature-sensitive ICP4 protein (lesion maps to the C-terminal third). 
(72) 
d27-1 
(ICP27- null) 
Incapable of replication unless ICP27 is provided in trans; virus bears a 1.6 kb deletion 
that removes 80% of the ICP27 ORF. 
(68) 
22/n199 
(ICP22- null) 
Virus replicates like wild-type in cell culture but fails to replicate in animals; virus 
synthesizes the first 198 of 420 amino acids of ICP22. 
(70) 
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Table 2 
Description of ∆E1-E3 adenovirus vectors 
Virus Promoter / Gene product Reference 
Ad-null TRE promoter / no gene product (10) 
Ad-ICP0 TRE  promoter / wild-type ICP0 (775 amino acids) (10) 
Ad-n212 
TRE promoter / N-terminus of ICP0 (211 of 775 amino 
acids) 
(10) 
Ad-ICP4 TRE  promoter / wild-type ICP4 (1298 amino acids) (10) 
Ad.CMV-TetOn CMV promoter / TetOn (rtTA) protein (10) 
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CHAPTER 3: RESULTS                                                                  
 
3.1. GENE REGULATION OF ICP0 
 
3.1.1. Characterization of HSV viruses that express GFP-tagged ICP0  
Three ICP0+GFP genes were constructed that encoded GFP-tagged ICP0 
in which i. GFP replaced amino acids 1 to 11 of the 775-amino acid ICP0 protein 
(ICP0+GFP-12); ii. GFP was inserted between amino acids 23 and 24 of ICP0 
(ICP0+GFP-24); or iii. GFP was inserted between amino acids 104 and 105 of ICP0 
(ICP0+GFP-105) (Fig. 1A).  An ICP0-null control gene, the ICP0-GFP gene, encoded 
only the N-terminal 104 amino acids of ICP0 fused to GFP (Fig. 1A).  Chimeric 
ICP0GFP genes were introduced into the LAT-ICP0 locus of HSV-1 strain KOS by 
homologous recombination to yield HSV-1 0-GFP, 0+GFP12, 0+GFP24, or 
0+GFP105 (Fig. 1B).   Northern blot analysis verified that each of these viruses 
synthesized the predicted 3.5 kb ICP0GFP mRNA (Fig. 1C).  GFP-tagged ICP0 
proteins were analyzed by two-color Western blot analysis.  In cells infected with 
wild-type HSV-1 KOS or KOS-GFP, ICP0-specific monoclonal antibody H1083 
labeled the 110 kDa ICP0 protein (red band in Fig. 1D).  In addition, the GFP-
expressing recombinant virus, KOS-GFP (75), also encoded an ~30 kDa GFP 
protein that was labeled by rabbit anti-GFP antibody (green band in Fig. 1D).  
HSV-1 0-GFP encoded a truncated ~55 kDa protein that was only labeled by the 
GFP-specific antibody, whereas the 0+GFP viruses encoded ~140 kDa ICP0+GFP-
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12, -24, and -105 proteins that were labeled with both ICP0- and GFP-specific 
antibodies (yellow bands in Fig. 1D). 
The functionality of ICP0+GFP-12, -24, and -105 proteins was compared to ICP0.  
Wild-type HSV-1 formed plaques with 100% efficiency in Vero cells relative to the 
number of plaques that formed in ICP0-complementing L7 cells (Fig. 1E).  In 
contrast, only ~1% of HSV-1 0-GFP (ICP0-) viruses formed plaques in Vero cells 
(Fig. 1E).  Each HSV-1 0+GFP virus formed plaques in Vero cells at ~66% 
efficiency relative to the number of plaques that formed in ICP0-complementing 
L7 cells (Fig. 1E).  Thus, ICP0+GFP-12, -24, or -105 protein each retained sufficient 
activity to promote HSV-1 plaque formation with 45-fold greater efficiency than 
the ICP0- null control virus, HSV-1 0-GFP. 
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Figure 1 
Characterization of HSV-1 viruses that express GFP-tagged ICP0. 
(A) Schematic of the wild-type or chimeric ICP0 genes in wild-type HSV-1 strain 
KOS or the recombinant viruses, HSV-1 0+GFP12, 0+GFP24, and 0+GFP105, and 0-
GFP.  (B) Southern blot analysis of the ICP0 locus of HSV-1 KOS versus HSV-1 
recombinant viruses based on hybridization of an ICP0 intron1-specific probe to 
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DNA digested with StuI and HpaI (ICP0 gene), StuI and BamHI (exon 1 
fragment), or PshAI and BssHII (exon 2 fragment).  (C) Northern blot analysis 
with an ICP0- versus GFP-specific probes hybridized to 10 µg total RNA isolated 
from Vero cells that were uninfected (no virus) or were infected with the specified 
HSV-1 viruses (MOI=10; RNA harvested 12 hours p.i.).  (D) Two-color Western 
blot analysis of cells that were uninfected (no virus) or were infected with the 
specified HSV-1 viruses (MOI=10; protein harvested 18 hours p.i.).  (E) Efficiency 
of plaque formation by HSV-1 KOS, 0-GFP, 0+GFP12, 0+GFP24, or 0+GFP105 in 
Vero cells relative to the number of plaques that formed in ICP0-complementing 
L7 cells (mean ± sem; n=3 cultures per group). 
 
3.1.2. Inefficient ICP0-GFP mRNA synthesis from HSV-1 0-GFP in the absence 
of ICP0  
ICP0 has been described as a promiscuous transcriptional activator (3, 
20, 84). We reasoned that ICP0 should act in a positive-feedback loop to 
promote mRNA synthesis from its own gene, the ICP0 gene. To test this 
inference, an ICP0-expressing adenovirus vector, Ad-ICP0, was compared to a 
control vector, Ad-n212 (Table 2), for its capacity to stimulate the expression of 
the ICP0-GFP reporter gene embedded in the native LAT-ICP0 locus of HSV-1 0-
GFP. 
In an initial test, cells were pre-treated with vehicle, Ad-n212, or Ad-ICP0, 
and were inoculated 12 hours later with 2.5 pfu per cell of HSV-1 0-GFP.  When 
compared at 12 hours post-inoculation (p.i.), HSV-1 0-GFP expressed barely 
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detectable levels of ICP0-GFP fluorescence in cells pre-treated with vehicle or Ad-
n212 (Figure 2A).  In contrast, pre-treatment with Ad-ICP0 allowed HSV-1 0-GFP 
to express high levels of ICP0-GFP fluorescence (Figure 2A). 
Northern blot analysis was conducted to determine if adenovirus-encoded 
ICP0 stimulated ICP0-GFP mRNA accumulation in HSV-1 0-GFP-infected cells.  
Vero cells were inoculated with 0 to 10 pfu of Ad-ICP0, and were inoculated 12 
hours later with 2.5 pfu per cell of HSV-1 0-GFP.  Northern blot analysis with a 
GFP-specific probe demonstrated that Ad-ICP0 stimulated a 5-fold increase in 
ICP0-GFP mRNA levels and did so in a dose-dependent manner (Figure 2B, D).  
In contrast, Ad-n212 had no effect on ICP0-GFP mRNA levels (Figure 2C, D).  
Therefore, exogenous ICP0 stimulated the accumulation of ICP0-GFP mRNA in 
cells inoculated with HSV-1 0-GFP. 
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Figure 2 
ICP0 stimulates HSV ICP0-GFP gene expression. 
(A) Photomicrographs of ICP0-GFP protein fluorescence in Vero cells inoculated 
with 2.5 pfu per cell of HSV-1 0-GFP at 12 hours p.i., which were pre-treated with 
either vehicle or 10 pfu per cell of Ad-n212 or Ad-ICP0 for 12 hours (20x 
magnification).  The TRE promoters in Ad-n212 and Ad-ICP0 were induced with 
20 pfu per cell of Ad.CMV-TetOn and 10 µM doxycycline.  (B and C) Northern 
blot comparison of ICP0-GFP mRNA levels in cells that were uninfected (UI) or 
were inoculated with 2.5 pfu per cell of HSV-1 0-GFP and 0 to 10 pfu per cell of 
(B) Ad-ICP0 or (C) Ad-n212 (10 µg RNA per lane; RNA harvested at 12 hours 
p.i.).  (D) ICP0-GFP mRNA levels plotted as a function of the MOI of adenovirus in 
the pre-treatment. 
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3.1.3. Efficient ICP0-GFP mRNA synthesis from HSV-1 0-GFP when protein 
synthesis is blocked 
We were interested to determine how ICP0 influences the activity of the 
ICP0-GFP gene in cells inoculated with HSV-1 0-GFP.  One possibility was that 
ICP0 induced mRNA synthesis from all of HSV-1 0-GFP’s genes, including the 
ICP0-GFP gene (Figure 3A).  A second possibility was that absence of ICP0 
allowed a repressor such as PML (18) or HDAC1/2-CoREST-REST (20) to 
silence all of HSV-1 0-GFP’s genes including the ICP0-GFP gene (Figure 3B, red 
line).  Under this latter hypothesis, ICP0 might stimulate ICP0-GFP mRNA 
synthesis by antagonizing the repressor of the ICP0-GFP gene (Figure 3B, green 
line).  An experiment was conducted to evaluate the relative likelihood of these 
two possibilities. 
The effect of Ad-ICP0 versus Ad-n212 was compared in cells inoculated 
with MOIs of 0.1 to 2.0 pfu per cell of HSV-1 0-GFP.  As expected, HSV-1 0-GFP 
expressed ICP0-GFP mRNA at all MOIs so long as ICP0 was provided in trans 
from Ad-ICP0 (Figure 3C).  In cells treated with the Ad-n212 control vector, HSV-
1 0-GFP failed to synthesize detectable levels of ICP0-GFP mRNA at MOIs below 
0.9 pfu per cell (Figure 3D).  At an MOI of 0.9 pfu per cell of HSV-1 0-GFP, 34-
fold higher levels of ICP0-GFP mRNA were noted in cells treated with Ad-ICP0 
relative to cells treated with Ad-n212 (Figure 3E).  Thus, efficient ICP0-GFP mRNA 
accumulation was highly dependent on ICP0 at low multiplicities of HSV infection. 
The mechanism by which ICP0 promoted ICP0-GFP mRNA accumulation 
was unclear.  Two possibilities included ICP0-dependent induction of ICP0-GFP 
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mRNA synthesis (Figure 3A) or ICP0-dependent antirepression of ICP0-GFP 
mRNA synthesis (Figure 3B).  To differentiate between these possibilities, cells 
were inoculated with Ad-ICP0 or Ad-n212 for twelve hours, and then cells were 
treated with cycloheximide at the time of HSV-1 0-GFP inoculation.  Thus, Ad-
ICP0’s capacity to stimulate ICP0-GFP mRNA accumulation could be evaluated in 
the relative absence of other activators and/or repressors that formed in HSV-1 
infected cells. 
As expected, cells pre-treated with Ad-ICP0 expressed high levels of 
ICP0-GFP mRNA despite the cycloheximide block to the synthesis of other HSV 
proteins (Figure 3F, H).  However, to our surprise, a similar result was observed 
in Ad-n212-treated cells treated with cycloheximide (Figure 3G, H).  Thus, when 
protein synthesis was blocked in HSV-infected cells, ICP0 was no longer required 
for the efficient synthesis of ICP0-GFP mRNA (Figure 3G).  These findings argued 
against the hypothesis that ICP0 was required to actively induce ICP0-GFP mRNA 
synthesis (Figure 3A).  Rather, the results suggested that ICP0 antagonized a 
repressor of the ICP0-GFP gene that was synthesized de novo in HSV-infected 
cells (Figure 3B, green line).  Further tests were conducted to explore the validity 
of this hypothesis. 
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Figure 3 
ICP0 de-represses HSV ICP0-GFP gene expression. 
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(A and B)  Alternative models by which ICP0 may stimulate ICP0-GFP gene 
activity.  (A) An ICP0 induction model predicts that ICP0 will be required to 
induce the ICP0-GFP gene to its full activity (green line), whereas efficient ICP0-GFP 
gene expression will not occur in the absence of ICP0 (blue line). (B) An ICP0 
antirepression model predicts that i. a repressor will silence the ICP0-GFP gene 
when ICP0 fails to accumulate (red line), ii. ICP0 prevents the repressor from 
silencing the ICP0-GFP gene (green line), and iii. ICP0 is not required for efficient 
ICP0-GFP gene expression when the repressor is absent (blue line).  (C, D, F, G) 
Northern blots of ICP0-GFP mRNA isolated from Vero cells inoculated with MOIs 
of 0.1 to 2 pfu per cell of HSV-1 0-GFP (RNA harvested 12 hours p.i.; 10 µg per 
lane).  Vero cells were pre-treated with 10 pfu per cell of (C, F) Ad-ICP0 or (D, G) 
Ad-n212 whose TRE promoters were induced with 20 pfu per cell of Ad.CMV-
TetOn and 10 µM doxycycline.  Cells were treated with (C, D) vehicle or (F, G) 
200 µM cycloheximide at the time of HSV-1 0-GFP inoculation. (E, H) ICP0-GFP 
mRNA levels are plotted as a function of the MOI of HSV-1 0-GFP used to 
inoculate Vero cells treated with (E) vehicle or (H) cycloheximide. 
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3.1.4. Testing the predictions of a repression-antirepression model of ICP0 
gene regulation 
Three predictions followed from an hypothesis that HSV-1 ICP0 gene 
activity was regulated by a process of repression and antirepression:  i. HSV-1 
ICP0- and ICP0+ viruses should express high and equivalent levels of ICP0 
mRNA when synthesis of the repressor was blocked with cycloheximide (Figure 
3B, blue line); ii. an HSV-1 ICP0+ virus should efficiently express ICP0 mRNA 
when the repressor accumulated in HSV-infected cells (Figure 3B, green line); 
and iii. an HSV-1 ICP0 - virus should exhibit little to no ICP0 mRNA synthesis 
when the repressor accumulated in the absence of ICP0 (Figure 3B, red line). 
As an initial test of these predictions, the relative expression of ICP0-GFP or 
ICP0+GFP-105 fluorescent reporter proteins was compared in cells inoculated with 
2.5 pfu per cell of HSV-1 0-GFP (ICP0-) versus HSV-1 0+GFP105 (ICP0+).  In 
vehicle-treated cells, HSV-1 0-GFP expressed barely detectable levels of ICP0-
GFP fluorescence, whereas HSV-1 0+GFP105 expressed ICP0+GFP-105 fluorescence 
to readily detectable levels (Figure 4A).  In contrast, when protein synthesis was 
inhibited for the first 6 hours of infection with cycloheximide, then both ICP0-GFP 
and ICP0+GFP-105 fluorescent proteins accumulated to high levels by 6 hours post-
release from the cycloheximide block (Figure 4B).  Quantification by flow 
cytometry (85) demonstrated that ICP0-GFP and ICP0+GFP-105 fluorescent proteins 
accumulated to high and equivalent levels following release from a cycloheximide 
block (not shown). 
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The relative expression of ICP0-GFP or ICP0+GFP-105 mRNA was compared 
in cells inoculated with HSV-1 0-GFP versus 0+GFP105.  When protein translation 
was allowed to occur, HSV-1 0-GFP produced levels of ICP0-GFP mRNA that were 
barely detectable between 3 and 12 hours p.i. (Figure 4C).  When cycloheximide 
was used to block protein synthesis, ICP0-GFP mRNA levels accumulated to 
levels that were ~90 times background in HSV-1 0-GFP-infected cells (Figure 4C, 
E).  In contrast, the onset of protein translation did not prevent an ICP0+ virus, 
HSV-1 0+GFP105, from expressing ICP0+GFP-105 mRNA to levels that were ~20 
times background (Figure 4D, E).  When protein synthesis was inhibited with 
cycloheximide, HSV-1 0+GFP105 expressed ~5-fold higher levels of ICP0+GFP-105 
mRNA (Figure 4D, E).  As predicted, cycloheximide treatment allowed HSV-1 0-
GFP and 0+GFP105 to express high and equivalent levels of ICP0GFP mRNA 
(Figure 4E).  Control experiments verified that cycloheximide blocked HSV-1 L 
mRNA synthesis (i.e., glycoprotein D mRNA), but had only a negligible effect on 
cellular GAPDH mRNA levels (not shown). 
These findings were consistent with the predictions of a repression-
antirepression model of ICP0 gene regulation (Figure 3B).  However, questions 
remained about the identity of the de novo repressor that inhibited ICP0 mRNA 
synthesis in HSV-1 0-GFP-infected cells.  Alternatively, it was possible that 
cycloheximide stimulated synthesis of all HSV mRNAs including ICP0-GFP mRNA 
in a non-specific manner (16).  Further experiments were conducted to 
differentiate between these possibilities. 
34 
 
 
Figure 4 
De novo repression of HSV ICP0GFP mRNA accumulation is antagonized  
by a GFP-tagged ICP0 protein. 
(A and B) Photomicrographs of ICP0-GFP and ICP0+GFP-105 reporter protein 
fluorescence in Vero cells 12 hours after inoculation with 2.5 pfu per cell of HSV-
1 0-GFP or 0+GFP105 (20x magnification).  Cells were treated with either (A) 
medium containing no drug (vehicle) from 0 to 12 hours p.i., or (B) 200 µM 
cycloheximide from -0.5 to 6 hours p.i. followed by vehicle from 6 to 12 hours p.i.  
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(C and D) Representative Northern blots of (C) ICP0-GFP mRNA or (D) ICP0+GFP-
105 mRNA harvested between 3 and 12 hours after inoculation with 2.5 pfu per 
cell of HSV-1 0-GFP or 0+GFP105, respectively.  Cells were treated with vehicle or 
200 µM cycloheximide until the indicated time of RNA harvest (10 µg per lane).  
(E) Mean ± sd of ICP0-GFP and ICP0+GFP-105 mRNA levels plotted as a function of 
time of RNA harvest (n=2 per group). 
 
3.1.5. Cycloheximide stimulates HSV ICP0 gene expression in a VP16-
dependent manner 
VP16 carried in HSV virions binds six VP16-responsive elements in the 
ICP0 promoter at the outset of infection (Figure 5A), and thus VP16 induces 
ICP0 mRNA synthesis (5, 86).  An experiment was conducted to determine if 
cycloheximide’s effect on steady-state ICP0 mRNA levels was the result of a 
VP16-dependent process, or rather was due to a myriad of non-specific effects 
that should operate with equal efficiency in the presence or absence of VP16. 
ICP0 mRNA accumulation was compared in cells inoculated with 2.5 pfu 
per cell of wild-type HSV-1 KOS, the ICP0- virus n212 (73), or the VP16- virus 
RP4 (74) (Table 1).  When protein synthesis was allowed to occur, wild-type 
HSV-1 expressed ICP0 mRNA to levels that were 28-fold above background, 
whereas an ICP0- virus and VP16- virus expressed ICP0 mRNA to levels that 
were only 4-fold above background (Figure 5B, C).  When protein synthesis was 
blocked with cycloheximide, the VP16+ viruses exhibited a robust increase in 
ICP0 mRNA levels; consequently, wild-type HSV and the ICP0- virus expressed 
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high and equivalent levels of ICP0 mRNA in cycloheximide-treated cells  (Figure 
5B, C).  In contrast, the VP16- virus failed to efficiently express ICP0 mRNA in 
either vehicle- or cycloheximide-treated cells (Figure 5C).  Thus, cycloheximide 
was incapable of stimulating ICP0 mRNA accumulation in the absence of VP16.  
These data argued against the possibilities that cycloheximide might increase 
ICP0 mRNA abundance by 1. decreasing the rate of ICP0 mRNA turnover, or by 
2. stimulating a non-specific increase in the rate of transcription of all genes, 
including the ICP0 gene.  Rather, the data were consistent with a hypothesis that 
cycloheximide blocked the formation of a de novo repressor of the ICP0 gene 
that was dominant over the HSV-specific inducer of the ICP0 gene, VP16. 
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Figure 5 
Cycloheximide increases ICP0 gene expression  
in a VP16-dependent manner. 
(A) Schematic of ICP0 promoter, which indicates the positions of six distal VP16-
responsive elements (VREs), a proximal ICP4-binding site (4BS), and the TATA-
box of the ICP0 gene. (B) Representative Northern blot of ICP0 mRNA in Vero 
cells that were uninfected (UI) or were inoculated with 2.5 pfu per cell of HSV-1 
KOS, n212 (ICP0-), or RP4 (VP16-), and which were treated with vehicle or 200 
µM cycloheximide from -0.5 to 12 hours p.i., at which time total RNA was 
harvested (10 µg per lane).  (C) Mean ± sem of ICP0 mRNA levels in KOS, n212, 
or RP4-infected cells (n=3 per group). Asterisks denote significant differences 
between vehicle- and cycloheximide-treated cells inoculated with the same virus 
(p<0.01; two-tailed Student’s t-test). 
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3.1.6. De novo repression of HSV ICP0 gene expression is ICP4-dependent 
There is evidence that inhibition of protein synthesis causes all of HSV’s 
IE mRNAs to be overexpressed (87).  One interpretation that has been offered is 
that cycloheximide’s effect on HSV mRNA synthesis is global and non-specific 
(16).  However, there is a second, biologically important hypothesis that has not 
been adequately considered.  As well as HSV ICP4’s function as an essential 
activator of E and L mRNA transcription (88), ICP4 may function as a repressor 
of IE mRNA transcription (72).  To determine if ICP4 contributed to de novo 
repression of the ICP0 gene, ICP0 mRNA accumulation was compared in cells 
inoculated with HSV-1 mutants deficient in the IE regulatory proteins ICP0, 
ICP27, ICP22, or ICP4 (Table 1). 
Regardless of their different genotypes, 2.5 pfu per cell of each HSV-1 
VP16+ virus yielded high and equivalent levels of ICP0 mRNA in cycloheximide-
treated cultures (Figure 6A).  The ICP0- virus, n212, expressed very low levels of 
ICP0 mRNA when protein translation was allowed to occur, whereas each of the 
ICP0+ viruses expressed ICP0 mRNA to levels that were readily detectable in 
vehicle-treated cells (Figure 6A).  Wild-type HSV-1 KOS expressed 3.5 ± 0.4-fold 
lower levels of ICP0 mRNA in vehicle-treated cells relative to cycloheximide-
treated controls (Figure 6A, B).  Likewise, the ICP27- and ICP22- viruses, d27-1 
(68) and 22/n199 (70), expressed 4- to 5-fold less ICP0 mRNA in vehicle-treated 
cells relative to cycloheximide-treated controls (Figure 6A, B).  These results 
suggested that the de novo repressor of ICP0 mRNA synthesis formed efficiently 
in the absence of ICP22, ICP27, or the ~70 HSV E and L proteins whose 
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synthesis was ICP27-dependent (68).  In contrast, an ICP4- virus, n12 (71), 
expressed high and equivalent levels of ICP0 mRNA in vehicle- and 
cycloheximide-treated cells (Figure 6A, B).  Therefore, de novo repression of 
ICP0 mRNA accumulation appeared to be dependent upon the synthesis of 
ICP4. 
An independent test was conducted to corroborate this interpretation.  
Vero cells were inoculated with 2.5 pfu per cell of HSV-1 KOS (ICP4+) or HSV-1 
tsB21 (ICP4ts), which bears a temperature-sensitive lesion in the C-terminus of 
ICP4; this mutation renders ICP4 non-functional at a temperature of 39.5 ºC (72).  
At 34.0º, 37.0º, and 39.5ºC, wild-type HSV-1 KOS expressed ~3-fold less ICP0 
mRNA in vehicle-treated cells relative to cycloheximide-treated controls (Figure 
6C, D).  Likewise, HSV-1 tsB21 expressed 2.9- and 2.3-fold less ICP0 mRNA in 
vehicle-treated cells at 34.0º and 37.0ºC, respectively, relative to cycloheximide-
treated controls (Figure 6C, D).  In contrast, at the non-permissive temperature of 
39.5ºC, HSV-1 tsB21 expressed equivalent levels of ICP0 mRNA in both vehicle- 
and cycloheximide-treated cells (Figure 6C, D).  Collectively these results 
indicated that de novo repression of ICP0 mRNA accumulation was dependent 
upon the synthesis of a biologically active form of HSV’s major transcriptional 
regulator, ICP4. 
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Figure 6 
De novo repression of HSV ICP0 gene expression is ICP4-dependent. 
(A) Representative Northern blot of ICP0 mRNA in Vero cells that were 
uninfected (UI) or were inoculated with 2.5 pfu per cell of HSV-1 KOS (wild-type), 
n212 (ICP0-), dl27-1 (ICP27-), 22/n199 (ICP22-), or n12 (ICP4-), which were 
treated with vehicle or 200 µM cycloheximide from -0.5 to 6 hours p.i., at which 
time total RNA was harvested (10 µg per lane).  (B) Mean ± sem fold-reduction in 
ICP0 mRNA levels in vehicle-treated cells relative to cycloheximide-treated 
controls (fold-reduction = mRNA CHX ÷ mRNA VEH; n=4 per group). (C) 
Representative Northern blot of ICP0 mRNA in Vero cells inoculated with 2.5 pfu 
per cell of KOS (ICP4+) or HSV-1 tsB21 (ICP4 ts).  Vehicle- and cycloheximide-
treated cultures were incubated in CO2 chambers at 34.0, 37.0, or 39.5º C, and 
total RNA was harvested at 6 hours p.i. (10 µg per lane). (D) Mean ± sem fold-
reduction in ICP0 mRNA levels plotted as a function of incubation temperature 
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(fold-reduction = mRNA CHX ÷ mRNA VEH; n=4 per group).  In panels B and D, 
asterisks denote fold-reductions in ICP0 mRNA that significantly differ from the 
value of 1, which is predicted by a null hypothesis that cycloheximide will have no 
effect on ICP0 mRNA accumulation in HSV-infected cells (p<0.01; two-tailed 
Student’s t-test). 
 
3.1.7. De novo repression of HSV ICP0GFP reporter genes is ICP4-binding-
site-dependent 
A consensus ICP4-binding site (ATCGTC) occurs 40-bp upstream of the 
TATA box in the ICP0 promoter (38, 89).  To determine if ICP4 binding to the 
ICP0 promoter contributed to de novo repression of ICP0GFP mRNA synthesis, 
the recombinant viruses HSV-1 0-4BS- and 0+4BS- were constructed which were 
equivalent to HSV-1 0-GFP and 0+GFP105, respectively, but carried a 4-bp 
deletion in the ICP4-binding site in the ICP0 promoter (Figure 7A). 
A test was conducted to determine if disruption of the ICP4-binding site 
might alleviate de novo repression of the ICP0-GFP gene.  Vero cells were 
inoculated with 5 pfu per cell of HSV-1 0-GFP or 0-4BS-, and ICP0-GFP 
fluorescence was compared at 12 hours p.i. (Figure 7B).  In cells inoculated with 
HSV-1 0-GFP, ICP0-GFP fluorescence was barely visible (Figure 7B).  In contrast, 
ICP0-GFP fluorescence was readily detected in cells inoculated with HSV-1 0-4BS- 
(Figure 7B). Likewise, ICP0+GFP-105 fluorescence accumulated to appreciably 
higher levels in cells inoculated with HSV-1 0+4BS- relative to HSV-1 0+GFP105 
(Figure 7C).  These observations suggested that disruption of the proximal ICP4-
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binding site in the ICP0 promoter significantly alleviated de novo repression of 
the ICP0-GFP and ICP0+GFP-105 genes. 
To corroborate this interpretation, accumulation of the 3.5 kb ICP0GFP RNA 
species was compared in cells inoculated with 5 pfu per cell of HSV-1 0-GFP, 0-
4BS-, 0+GFP105, or 0+4BS- (Figure 7D).  Each virus yielded high levels of ICP0-
GFP or ICP0+GFP-105 mRNA in cycloheximide-treated cultures (Figure 7D).  HSV-1 
0-GFP exhibited a 13 ±1-fold repression of ICP0-GFP mRNA synthesis in vehicle-
treated cells relative to cycloheximide-treated controls (Figure 7D, 7E).  
Disruption of the ICP4-binding site in the ICP0 promoter alleviated de novo 
repression by 4-fold, and thus HSV-1 0-4BS- exhibited only a 3.3 ± 0.5-fold 
reduction in ICP0-GFP mRNA in vehicle-treated cells (Figure 7D, 7E).  Disruption 
of the ICP4-binding site in the ICP0-GFP gene increased the efficiency of ICP0GFP 
mRNA synthesis to the same extent as synthesis of a biologically active ICP0 
protein; thus, HSV-1 0-4BS- and 0+GFP105 both exhibited a 3.3-fold reduction in 
ICP0GFP mRNA levels in vehicle-treated cells relative to their respective 
cycloheximide-treated controls (Figure 7D, 7E).  Disruption of the ICP4-binding 
site in the ICP0 promoter of HSV-1 0+4BS- resulted in a significant de-repression; 
thus ICP0+GFP-105 mRNA levels in vehicle-treated cells infected with HSV-1 
0+4BS- were only 2.1 ± 0.2-fold lower than cycloheximide-treated controls (Figure 
7D, 7E).  Collectively, these observations indicated that the magnitude of de 
novo repression of ICP0GFP mRNA synthesis was significantly dependent upon 
the ICP4-binding site proximal to the transcriptional start site of the ICP0 gene 
(Figure 7A). 
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Figure 7 
De novo repression of ICP0GFP gene expression  
is ICP4-binding-site-dependent. 
(A) Schematic of the ICP4 DNA-binding site (4BS) deletion in HSV-1 0-GFP and 
0+GFP105.  All four viruses transcribe 3.5 kb ICP0GFP mRNAs, but HSV-1 0-4BS- 
and 0+4BS- are deleted of bases -43 to -40 relative to the TATA box of the 
ICP0GFP gene, which disrupts the consensus ICP4-binding site, 5’-ATCGTC-3’.  
(B and C) Photomicrographs of ICP0-GFP and ICP0+GFP-105 fluorescent protein 
accumulation in Vero cells 12 hours after inoculation with 5 pfu per cell of (B) 
HSV-1 0-GFP versus 0-4BS- or (C) HSV-1 0+GFP105 versus 0+4BS- (20x 
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magnification).  (D) Representative Northern blots of ICP0GFP mRNA 
accumulation in Vero cells that were uninfected (UI) or were inoculated with 5 pfu 
per cell of HSV-1 0-GFP (ICP0-), 0-4BS- (ICP0-), 0+GFP105 (ICP0+), or 0+4BS- 
(ICP0+), and which were treated with vehicle or 200 µM cycloheximide from -0.5 
to 12 hours p.i., at which time total RNA was harvested (10 µg per lane).  (E) 
Mean ± sem fold-reduction in ICP0GFP mRNA levels in vehicle-treated cells 
relative to cycloheximide-treated controls (fold-reduction = mRNA CHX ÷ mRNA VEH; 
n=3 per group).  Asterisks denote significant differences in fold-reduction in 
ICP0GFP mRNA levels between the ICP0- viruses, HSV-1 0-GFP versus 0-4BS- 
(p<0.001), and between the ICP0+ viruses, HSV-1 0+GFP105 versus 0+4BS- 
(p<0.01; two-tailed Student’s t-test). 
 
3.1.8. Adenovirus-encoded ICP4 substitutes for the de novo repressor of 
the HSV ICP0-GFP gene 
Our results raised the possibility that the de novo repressor of ICP0 mRNA 
synthesis was not a cellular protein, but rather was the HSV ICP4 protein 
because 1. loss of ICP4 function de-repressed ICP0 mRNA synthesis to the 
same extent as cycloheximide treatment (Figure 6), and 2. a 4-bp deletion that 
removed a single ICP4-binding site significantly alleviated de novo repression of 
ICP0 mRNA synthesis (Figure 7).  Based on this hypothesis, it was predicted that 
pre-treatment of Vero cells with an ICP4-expressing adenovirus should negate 
cycloheximide’s capacity to stimulate ICP0-GFP mRNA synthesis in HSV-1 0-GFP-
infected cells. 
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 To test this prediction, Vero cells were infected with 0 to 250 pfu per cell 
of Ad-ICP4 or a null control vector, and cells were inoculated 12 hours later with 
HSV-1 0-GFP in the presence of cycloheximide.  As expected, cells that received 
no adenovirus vector and which were inoculated with HSV-1 0-GFP in the 
presence of cycloheximide expressed high levels of ICP0-GFP mRNA (Figure 8A).  
However, when Vero cells were pre-treated with Ad-ICP4, cycloheximide’s 
capacity to stimulate ICP0-GFP mRNA synthesis dissipated and this inhibition was 
adenovirus dose-dependent (Figure 8A).  Despite cycloheximide treatment, the 
highest MOI of Ad-ICP4 caused a 42-fold reduction in ICP0-GFP mRNA levels in 
HSV-1 0-GFP-infected cells (Figure 8C).  This was not a non-specific effect of the 
adenovirus vector, as MOIs of 10 to 250 pfu per cell of Ad-null did not reduce the 
efficiency of ICP0-GFP mRNA synthesis in HSV-1 0-GFP-infected cells treated with 
cycloheximide (Figure 8A). 
To verify that Ad-ICP4’s capacity to repress ICP0-GFP mRNA synthesis 
was ICP4-binding-site-dependent, the experiment was performed in parallel with 
HSV-1 0-4BS-.  Ad-ICP4 had a modest effect on ICP0-GFP mRNA synthesis in 
HSV-1 0-4BS--infected cells (Figure 8B).  However, the potency of inhibition was 
10-fold less than that observed in HSV-1 0-GFP-infected cells (Figure 8C).  
Specifically, an MOI of 250 pfu per cell of Ad-ICP4 produced only a 4.4-fold 
reduction in ICP0-GFP mRNA levels in HSV-1 0-4BS--infected cells treated with 
cycloheximide (Figure 8C).  Therefore, adenovirus-encoded ICP4 was sufficient 
to substitute for the de novo repressor of the ICP0-GFP gene (Figure 8C). 
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Figure 8 
Exogenous ICP4 substitutes for the de novo repressor of the ICP0-GFP gene. 
Representative Northern blots of ICP0-GFP mRNA levels in Vero cells treated with 
200 µM cycloheximide and inoculated with 5 pfu per cell of (A) HSV-1 0-GFP or 
(B) HSV-1 0-4BS-  (10 µg total RNA per lane; time of harvest = 12 hours p.i.).  
Twelve hours prior to HSV-1 inoculation, cells were pre-treated with 0, 10, 50, or 
250 pfu per cell of Ad-ICP4 or Ad-null whose TRE promoters were induced with 
20 pfu per cell of Ad.CMV-TetOn and 10 µM doxycycline.  (C) Mean ± sem fold-
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reduction in ICP0-GFP mRNA levels in HSV-1 0-GFP or 0-4BS- infected cells as a 
function of the MOI of Ad-ICP4 in the pre-treatment (n=3 per group).  Asterisks 
denote significant differences in Ad-ICP4-induced reductions in ICP0-GFP mRNA 
levels between HSV-1 0-GFP and 0-4BS- (p < 0.001; two-way analysis of 
variance). 
 
3.1.9. ICP0 physically interacts with the repressor of its gene, ICP4, in HSV-
infected cells 
A physical interaction between ICP0 and ICP4 might begin to explain how 
ICP0 influences ICP4’s activity as a transcriptional regulator.  The available 
evidence from far-Western blotting (81) and co-localization studies (80) 
suggested that ICP0 may physically interact with ICP4.  However, direct 
evidence was lacking to address whether or not ICP0 and ICP4 physically 
interact in the context of HSV-infected cells.  
To address this gap in knowledge, a recombinant virus was constructed 
that bore a FLAG epitope between amino acids 23 and 24 of ICP0, and which is 
referred to as HSV-1 0+FLAG24 (Figure 9A).  Southern blot analysis validated that 
the FLAG coding sequence was inserted in both copies of the ICP0 gene, and 
that HSV-1 0+FLAG24 grew with wild-type efficiency (not shown).  
Immunofluorescent staining verified that HSV-1 0+FLAG24 expressed a FLAG-
tagged protein that exhibited a nuclear-staining pattern typical of ICP0 during the 
IE phase of HSV infection (Figure 9B; 10 hours in cycloheximide → 6 hours in 
actinomycin D). 
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Immunoprecipitation experiments were performed to determine if ICP4 
physically interacted with FLAG-tagged ICP0.  Vero cells were inoculated with 
vehicle or 5 pfu per cell of HSV-1 KOS or 0+FLAG24 in the presence of 
cycloheximide (0 - 10 hours p.i.) followed by actinomycin D (10 - 16 hours p.i.), 
such that only viral IE proteins were efficiently synthesized.  Input levels of ICP4 
and ICP0 in each immunoprecipitation reaction were equivalent, as verified by 
Western blot analysis with monoclonal antibodies 58S and H1083, respectively 
(Figure 9C, top panel).  The remainder of each protein sample was 
immunoprecipitated with an anti-FLAG antibody-agarose conjugate under 
conditions of medium or high stringency, and immunoprecipitates were analyzed 
for the presence of ICP4. 
Significant amounts of ICP4 co-immunoprecipitated with FLAG-tagged 
ICP0 from lysates of HSV-1 0+FLAG24-infected cells (Figure 9C, middle panel).  
Non-specific pull down of ICP4 was negligible from lysates of uninfected Vero 
cells or KOS-infected cells (Figure 9C).  Therefore, the α-FLAG agarose only 
appeared to pull down ICP4 when the FLAG epitope was present in ICP0.  
Consistent with this interpretation, re-probing of the same blot with an ICP0-
specific monoclonal antibody, H1083, verified that anti-FLAG agarose efficiently 
pulled down the 110 kDa FLAG-tagged ICP0, but did not pull down wild-type 
ICP0 (Figure 9C, lower panel).  We conclude that ICP0 and ICP4 do indeed 
physically interact in HSV-infected cells, and propose that this interaction is likely 
relevant in explaining how ICP0 antagonizes ICP4’s capacity to silence ICP0 
mRNA synthesis from the HSV genome. 
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Figure 9 
ICP4 co-immunoprecipitates with FLAG-tagged ICP0. 
(A) Schematic of 30-bp FLAG coding sequence insertion in exon 2 of the ICP0 
gene in the HSV-1 recombinant virus, 0+FLAG24, in which a FLAG tag is inserted 
between amino acids 23 and 24 of ICP0.  (B and C)  Vero cells were inoculated 
with 5 pfu per cell of HSV-1 KOS (wild-type) or HSV-1 0+FLAG24, which were 
treated with 200 µM cycloheximide from -0.5 to 10 hours p.i., released into 
actinomycin D (10 µg / ml) from 10 to 16 hours p.i., and harvested for 
immunofluorescent staining or immunoprecipitation.  (B) Immunofluorescent 
staining with a FLAG-specific antibody and AlexaFluor 594-conjugated secondary 
antibody.  (C) Cells were harvested in an NP40-based buffer containing 150 mM 
NaCl (left panel) or RIPA buffer (right panel).  The relative abundance of ICP4 
and ICP0 was compared in 5% of total cell lysates (top panel), and the remainder 
was immunoprecipitated with anti-FLAG agarose.  Immunoprecipiates were 
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washed in 500 mM NaCl (left panel) or RIPA buffer (right panel) prior to 
electrophoresis and blotting, and were probed with ICP4-specific monoclonal 
antibody 58S (middle panel), followed by re-probing with ICP0-specific 
monoclonal antibody H1083 (bottom panel).  The relative locations of ICP4 and 
ICP0 are denoted by asterisks and open circles. 
 
3.2. FUNCTION OF ICP0         
 
3.2.1. GFP-tagged ICP0 is predominantly observed in the cytoplasm of HSV-
infected cells 
In cells transfected with the plasmids p0+GFP12, p0+GFP24, or p0+GFP105, 
the ICP0+GFP-12, -24, or -105 proteins each accumulated in the nuclei of transfected 
cells in a nuclear domain 10 (ND10)-like pattern (Fig. 10A-C; Ref. (30, 42)).  In 
contrast, the truncated ICP0-GFP protein was distributed in a nuclear and 
perinuclear pattern in cells transfected with the plasmid p0-GFP (Fig. 10D).  
When expressed in the context of HSV-1 infection, ICP0+GFP-12, -24, or -105 protein 
was predominantly observed in the cytoplasm of virus-infected cells.  For 
example, ICP0+GFP-12 was predominantly observed in the cytoplasm of cells at the 
outer edge of plaques formed by HSV-1 0+GFP12 (white arrow in Fig. 10E).  
Likewise, the ICP0+GFP-24 and ICP0+GFP-105 proteins were primarily detected in the 
cytoplasm of cells at the outer edge of plaques formed by HSV-1 0+GFP24 and 
HSV-1 0+GFP105, respectively (white arrows in Fig. 10F, 10G).  In contrast, the 
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ICP0-GFP peptide expressed by HSV-1 0-GFP accumulated throughout virus-
infected cells (Fig. 10H). 
The subcellular distribution of ICP0+GFP-24 protein was monitored in Vero 
cells inoculated with 10 pfu per cell of HSV-1 0+GFP24.  At 3 hours p.i., GFP-
tagged ICP0 was evident in the nuclei of many cells (Fig. 11A).  However, 
ICP0+GFP-24 only accumulated to high levels after 5 hours p.i., at which time the 
protein had translocated to the cytoplasm of most HSV-1 0+GFP24-infected cells 
(Fig. 11A).  To determine if the translocation of ICP0+GFP-24 was replication-
dependent, an HSV-1 ICP4- null virus was constructed, HSV-1 0+GFP24-Δ4.  In 
cells inoculated with HSV-1 0+GFP24-Δ4, the nuclear-to-cytoplasmic translocation 
of ICP0+GFP-24 occurred with kinetics similar to the ICP4+ virus (Fig. 11B).  
ICP0+GFP-24 was observed in bright perinuclear lines and globular bodies when 
overexpressed from the ICP4- null virus (Fig. 11B).  Intriguingly, this pattern of 
cytoplasmic ICP0 was equivalent to the findings of Knipe and Smith (1986) (48), 
who first described ICP0’s cytoplasmic distribution in cells inoculated with an 
HSV-1 ICP4 mutant.  Live-cell imaging of HSV-1 0+GFP24-Δ4-infected cells 
demonstrated that the cytoplasmic bodies in which ICP0+GFP-24 protein 
accumulated were highly mobile.  In addition, cytoplasmic ICP0+GFP-24 was often 
observed in linear arrays that encircled the nucleus (denoted by asterisks in Fig. 
11B). 
These observations raised questions both about the requirements for 
ICP0’s nuclear-to-cytoplasmic translocation, and what function ICP0 might fulfill 
in the cytoplasm of HSV-1 infected cells.   
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Figure 10 
GFP-tagged ICP0 is predominantly cytoplasmic in HSV-1 infected cells. 
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(A) ICP0+GFP-12, (B) ICP0+GFP-24, (C) ICP0+GFP-105, or (D) ICP0-GFP as seen in Vero 
cells 12 hours post transfection with the plasmids p0+GFP12, p0+GFP24, 
p0+GFP105, or p0-GFP, respectively.  Each plasmid was co-transfected with the 
plasmid pBHad.CMV-VP16 to induce the ICP0 promoter and expression of GFP-
tagged ICP0.  (E) ICP0+GFP-12, (F) ICP0+GFP-24, (G) ICP0+GFP-105, or (H) ICP0-GFP 
as seen in Vero cells 40 hours post inoculation with the HSV-1 recombinant 
viruses 0+GFP12, 0+GFP24, 0+GFP105, or 0-GFP, respectively.  In each panel, an 
entire plaque is shown on the right, and one edge of the plaque is magnified on 
the left.  White arrows denote HSV-1 infected cells in which GFP-tagged ICP0 
was abundant in the cytoplasm, but was not evident in the nuclei of HSV-1 
infected cells.  Scale bar = 10 µm. 
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Figure 11 
ICP0+GFP-24 translocates to the cytoplasm of HSV-1 infected cells  
in the presence or absence of ICP4. 
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ICP0+GFP-24 protein in Vero cells inoculated with 10 pfu per cell of HSV-1 0+GFP24 
(left column) or HSV-1 0+GFP24-∆4 (right column) between 3 and 8 hours p.i.  
White asterisks denote cells in which ICP0+GFP-24 was observed in a linear pattern 
encircling the nucleus of HSV-1 infected cells.  Scale bar = 10 µm. 
 
3.2.2. Cytoplasmic translocation of ICP0 is an early event in the HSV-1 
replication cycle 
To determine if cytoplasmic translocation of GFP-tagged ICP0 was 
dependent upon the synthesis of other HSV-1 IE, E, or late (L) proteins, chemical 
inhibitors were used to subdivide HSV-1 protein synthesis into its different 
phases.  Vero cells were treated with cycloheximide to block protein translation, 
and cells were inoculated with 5 pfu per cell of HSV-1 0+GFP105.  After allowing 6 
hours for the accumulation of viral IE mRNAs, cycloheximide was removed and 
cultures were released into medium containing either actinomycin D (mRNA 
synthesis inhibitor, Ref. (90)), acyclovir (DNA synthesis inhibitor, Ref. (91)) or 
vehicle (no inhibitor). 
In HSV-1 0+GFP105-infected cells released into medium containing 
actinomycin D,  ICP0+GFP-105 remained in the nuclei of >90% of cells at 1 and 4 
hours post-release from a cycloheximide block (Fig. 12A).  Thus, translocation of 
ICP0+GFP-105 failed to occur when only viral IE proteins were efficiently expressed.  
When HSV-1 0+GFP105-infected cells were released into medium containing 
acyclovir (IE and E proteins expressed), ICP0+GFP-105 was initially observed in 
nuclei, but translocated to the cytoplasm of most cells by 4 hours post-release 
(Fig. 12A).  Likewise, when cycloheximide treatment was followed with vehicle, 
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ICP0+GFP-105 translocated to the cytoplasm with similar kinetics (Fig. 12A).  
Parallel tests with HSV-1 0+GFP12, 0+GFP24, and 0+GFP24-Δ4 yielded equivalent 
results (not shown).  These results suggested that the nuclear-to-cytoplasmic 
translocation of ICP0+GFP-105 occurred during the E phase of HSV-1 replication. 
To determine if these results were relevant to wild-type ICP0, similar tests 
were performed with wild-type HSV-1 strain KOS (69).  When cycloheximide 
treatment was followed with actinomycin D, wild-type ICP0 was retained in the 
nuclei of KOS-infected cells at 4 hours post-release (Fig. 12B).  In contrast, when 
cycloheximide treatment was followed with acyclovir or vehicle, wild-type ICP0 
translocated to the cytoplasm by 4 hours post-release and was observed in 
globular and linear structures that encircled the nuclei of >90% of KOS-infected 
cells (Fig. 12B).  Therefore, both GFP-tagged ICP0 and wild-type ICP0 were 
predominantly nuclear during the IE phase of viral infection, but rapidly 
translocated to the cytoplasm when viral E protein synthesis was allowed to 
occur.  
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Figure 12 
ICP0 translocates to the cytoplasm during early phase of HSV-1 replication. 
(A) ICP0+GFP-105 protein in Vero cells inoculated with HSV-1 0+GFP105 following 
release from cycloheximide block.  Cultures were inoculated with 5 pfu per cell of 
0+GFP105, treated with 200 μM cycloheximide from -0.5 to 6 hours p.i., and 
released into medium containing actinomycin D (10 µg / ml), 300 µM acyclovir, or 
vehicle.  Cultures were photographed at 7 and 10 hours p.i.  (B) ICP0 in HSV-1 
KOS-infected Vero cells following release from cycloheximide block.  Cultures 
were inoculated with 5 pfu per cell of KOS, treated with cycloheximide from -0.5 
to 6 hours p.i., released into medium containing actinomycin D, acyclovir, or 
vehicle, and fixed for immunofluorescent staining at 7 and 10 hours p.i.  White 
asterisks denote cells in which ICP0 was observed in a linear pattern encircling 
the nucleus of HSV-1 infected cells.  Scale bar = 10 µm. 
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3.2.3. ICP0+GFP-105 disperses linear structures in the cytoplasm of HSV-1 
infected cells 
The cytoplasmic structures in which ICP0 accumulated did not appear to 
be mitochondria, lysosomes, Golgi apparatus, or endoplasmic reticulum (ER) 
based upon the failure of ICP0 to co-localize with MitoTracker dye (92), 
LysoTracker dye (93), Golgi marker β-COP (94), or the ER marker calreticulin 
(95).  Moreover, in early attempts to isolate the fluorescent-ICP0 labeled 
cytoplasmic bodies by density gradient sedimentation, it was noted that the 
bodies rapidly dispersed upon homogenization of cells in ice-cold buffer (not 
shown).  To gather further clues about the nature of these structures, live-cell 
imaging was used to study the dynamics of accumulation of ICP0+GFP-105 in the 
cytoplasm of HSV-1 0+GFP105-infected cells. 
Cycloheximide was used to alleviate ICP4-dependent repression of the 
ICP0GFP gene (39), such that ICP0+GFP-105 mRNA could accumulate to high levels 
and be synchronously translated upon cycloheximide release (39).  At 1 hour 
post-release, ICP0+GFP-105 was observed exclusively in the nuclei of HSV-1 
0+GFP105-infected cells (Table 3).  Between 2 and 4 hours post-release, 
ICP0+GFP-105 had partially or completely translocated to the cytoplasm of >90% of 
HSV-1 0+GFP105-infected cells (Table 3).  At 4 hours post-release, ICP0+GFP-105 
was observed in linear cytoplasmic structures in 16 ± 1% of 0+GFP105-infected 
cells (Table 3).  However, by 6 hours post-release, ICP0+GFP-105 was rarely 
observed in linear cytoplasmic structures (Table 3). 
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We considered the possibility that ICP0+GFP-105 might trigger the dispersal 
of cytoplasmic structures in much the same manner that ICP0 triggers the 
dispersal of PML nuclear bodies (30, 42).  To test this hypothesis, a recombinant 
virus was constructed, HSV-1 0ΔRING, which encoded a GFP-tagged ICP0∆RING 
protein that was deleted of amino acids 105 – 221, and thus lacked ICP0’s RING-
finger domain (15).  When cycloheximide-release experiments were performed in 
cells inoculated with HSV-1 0ΔRING, the ICP0∆RING protein accumulated in linear 
cytoplasmic structures between 2 and 6 hours post-release (Table 3).  
Intriguingly, ICP0∆RING was rarely observed in globular bodies, but rather the 
protein was observed almost exclusively in linear cytoplasmic structures (Table 
3).  These findings suggested that ICP0∆RING stably accumulated in linear 
cytoplasmic structures, whereas ICP0+GFP-105 triggered the dispersal of these 
structures upon accumulating at these sites. 
To test this hypothesis, live-cell imaging was used to track the fate of 
linear structures in which ICP0+GFP-105 accumulated.  Cells were inoculated with 
HSV-1 0+GFP105 and time-lapse photography was conducted between 4.0 and 
4.5 hours post-release from a cycloheximide block.  Linear, cytoplasmic arrays of 
ICP0+GFP-105 that initially encircled the nucleus were found to be unstable, and 
dispersed into smaller, globular bodies over a 10- to 20-minute time frame (Fig. 
13A).  In contrast, experiments with HSV-1 0ΔRING demonstrated that the 
ICP0∆RING protein stably accumulated in linear cytoplasmic structures which grew 
visibly in length and thickness between 4.0 and 4.5 hours post-release (Fig. 
13B).  This trend continued until 6 hours post-release, at which time the 
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experiment was terminated (not shown).  Therefore, ICP0+GFP-105 translocated to 
the cytoplasm, accumulated in linear cytoplasmic structures, and then triggered 
the dispersal of these structures in a RING-finger-dependent manner. 
 
Table 3 
Subcellular distribution of ICP0GFP in HSV-1 infected cells at times after 
release from a cycloheximide block a 
Virus Hours 
Subcellular distribution b Cytoplasmic pattern e 
ICP0GFP only 
in nucleus 
ICP0GFP in 
cytoplasm 
ICP0GFP 
in lines 
ICP0GFP 
in globules 
0+GFP105 
1 100 ± 0 c 0 ± 0 d 0 ± 0 f 0 ± 0 g 
2 9 ± 1 91 ± 1 2 ± 0 98 ± 0 
3 2 ± 0 98 ± 0 10 ± 1 90 ± 1 
4 2 ± 0 98 ± 0 16 ± 1 77 ± 1 
5 2 ± 0 98 ± 0 11 ± 1 81 ± 1 
6 1 ± 0 99 ± 0 1 ± 0 87 ± 1 
0ΔRING 
1 100 ± 0 0 ± 0 0 ± 0 0 ± 0 
2 40 ± 2 60 ± 2 96 ± 0 4 ± 0 
3 39 ± 1 61 ± 1 97 ± 0 3 ± 0 
4 34 ± 1 66 ± 1 99 ± 0 1 ± 0 
5 26 ± 1 74 ± 1 99 ± 0 1 ± 0 
6 22 ± 1 78 ± 1 99 ± 0 1 ± 0 
 
a Vero cells were inoculated with 5 pfu per cell of HSV-1 0+GFP105 or HSV-1 
0∆RING in the presence of 200 μM cycloheximide from -0.5 to 10 hours p.i., and 
were released into medium containing no drugs.  Cultures were photographed 
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between 1 and 6 hours post-release to record the position of all nuclei (visualized 
with Hoechst 33342) and the subcellular localization of ICP0+GFP-105 or ICP0∆RING.   
b Frequency of cells in which ICP0+GFP-105 or ICP0∆RING was observed exclusively in 
the nucleus (left column) versus cells in which proteins were observed in either 
the cytoplasm and nucleus or just in the cytoplasm (right column). 
c Frequency of cells (mean ± sem) in which ICP0+GFP-105 or ICP0∆RING was 
observed exclusively in the nucleus. The frequency reported at each time point 
was calculated as 100 x number of cells in which ICP0GFP was observed solely in 
the nucleus ÷ number of ICP0GFP+ cells.  Each value is based on n = 4 
independent cultures, and each estimate of frequency was based on n=400 
Hoechst+ cells.  Between 4 and 6 hours post-release, 95 ± 1% of cells in HSV-1 
inoculated cultures were positive for the ICP0+GFP-105 or ICP0∆RING proteins.    
d Frequency of cells (mean ± sem) in which ICP0+GFP-105 or ICP0∆RING was 
observed in the cytoplasm and nucleus, or just in the cytoplasm. Frequencies 
were calculated by the method described in footnote c. 
e Frequency of ICP0+GFP-105 or ICP0∆RING accumulating in linear arrays (left column) 
versus globular patterns (right column) in the cytoplasm of HSV-1 infected cells. 
f Frequency of cells (mean ± sem) in which ICP0+GFP-105 or ICP0∆RING were 
observed in linear cytoplasmic arrays that encircled Hoechst+ nuclei.  The 
frequency reported at each time point was calculated as 100 x number of cells 
containing linear arrays of ICP0GFP protein ÷ number of cells in which ICP0GFP 
was evident in the cytoplasm.  Each value is based on n = 4 independent 
cultures, and each estimate of frequency was based on n=400 Hoechst+ cells. 
g Frequency of cells (mean ± sem) in which ICP0+GFP-105 or ICP0∆RING were 
observed in globular, cytoplasmic bodies, which was calculated as described in 
footnote f. 
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Figure 13 
ICP0+GFP-105 disperses linear cytoplasmic structures  
in a RING-finger-dependent manner. 
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Vero cells were inoculated with 5 pfu per cell of (A) HSV-1 0+GFP105 or (B) HSV-
1 0∆RING in the presence of 200 μM cycloheximide from -0.5 to 10 hours p.i., 
and were released into medium containing no drugs.  Between 4.0 and 4.5 hours 
post-release, time-lapse photographs were collected of the ICP0+GFP-105 or 
ICP0∆RING proteins that encircled the nucleus of HSV-1 infected cells.  Scale bar 
= 10 µm. 
 
3.2.4. ICP0 co-localizes with disrupted microtubule networks in HSV-1 
infected cells 
The linear cytoplasmic structures in which ICP0+GFP-105 transiently 
accumulated were reminiscent of microtubule bundles formed by HSV-1’s VP22 
protein (56).  Therefore, we considered the possibility that ICP0+GFP-105 and 
ICP0∆RING proteins might associate with host cell microtubules.  To test this 
hypothesis, cycloheximide-release experiments were performed in cells 
inoculated with HSV-1 0ΔRING, HSV-1 0+GFP105, or wild-type HSV-1 KOS.  At 4 
hours post-release, cells were fixed and immunofluorescently stained for α-
tubulin and ICP0. 
In uninfected Vero cells, α-tubulin staining revealed a normal network of 
microtubules that radiated from the microtubule-organizing center at the 
periphery of the nucleus (Fig. 14).  In cells inoculated with HSV-1 0ΔRING, α-
tubulin staining revealed extensive thickening of microtubules into elongated 
bundles that circumscribed the nucleus, and co-localized with the ICP0∆RING 
protein (Fig. 14).  In cells inoculated with HSV-1 0+GFP105, α-tubulin staining 
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revealed that the microtubule network had dispersed into small α-tubulin+, 
globular bodies that co-localized with ICP0+GFP-105 (Fig. 14).  In cells inoculated 
with wild-type HSV-1 KOS, the host cell microtubule network was also disrupted, 
and α-tubulin was dispersed into α-tubulin+ globular bodies that co-localized with 
ICP0 (Fig. 14).  Although the ICP0∆RING protein bundled microtubules, it failed to 
trigger their dispersal into globular bodies (Fig. 14).  These results raised the 
possibility that HSV’s E3 ligase, ICP0, might contribute to microtubule 
disassembly in HSV-infected cells (55).  Further experiments were conducted to 
test the validity of this hypothesis. 
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Figure 14 
ICP0 co-localizes with reorganized microtubules in HSV-1 infected cells.   
Immunofluorescent staining of Vero cells that were uninfected (no virus) or that 
were inoculated with 5 pfu per cell of HSV-1 0ΔRING, HSV-1 0+GFP105, or wild-
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type HSV-1 strain KOS.  Cells were inoculated in the presence of 200 μM 
cycloheximide from -0.5 to 10 hours p.i., and were released into medium 
containing no drugs.  At 4 hours post-release, uninfected cells and KOS-infected 
cells were fixed and stained with antibodies against α-tubulin (rabbit IgG, Alexa 
Fluor 594) and ICP0 (mouse IgG, fluorescein).  Nuclei were counterstained with 
the DNA-binding dye Hoechst 33342.  HSV-1 0ΔRING and 0+GFP105-infected 
cells were fixed and stained for α-tubulin, and the ICP0∆RING and ICP0+GFP-105 
proteins were visualized using their GFP fluorophores.  Scale bar = 10 µm. 
 
3.2.5. ICP0∆RING protein accumulates in linear structures that are 
nocodazole-sensitive 
If microtubules did indeed provide the underlying scaffold on which 
ICP0∆RING protein accumulated in linear arrays (Fig. 13, 14), then inhibition of 
microtubule polymerization with nocodazole (96) should recapitulate the effect of 
ICP0’s RING finger domain.  Specifically, nocodazole treatment, like wild-type 
ICP0, should trigger microtubule disassembly and cause linear accumulations of 
ICP0∆RING protein to disperse into smaller bodies.  To test this prediction, cells 
were infected with HSV-1 0ΔRING in the presence of cycloheximide for 10 hours, 
and were released into medium containing no inhibitor.  Four hours later, the 
stability of linear arrays of ICP0∆RING protein was compared in the presence or 
absence of nocodazole. 
In the absence of nocodazole, ICP0∆RING protein stably accumulated in 
linear structures that encircled the nucleus of HSV-1 0ΔRING-infected cells 
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between 4.0 and 4.5 hours post-release (Fig. 15A).  In contrast, nocodazole 
treatment caused linear accumulations of ICP0∆RING protein to disperse into small 
globular bodies within 10 to 30 minutes, and the time required for dispersal 
varied in proportion to the thickness of each bundle (Fig. 15B).  Nocodazole-
induced, ICP0∆RING+ globular bodies were identical in appearance to α-tubulin+ 
globular bodies that co-localized with ICP0 and ICP0+GFP-105 (Fig. 14).  
Independent tests verified that nocodazole-induced, ICP0∆RING+ globular bodies 
were also α-tubulin+ (not shown). 
These observations indicated that the linear cytoplasmic structures in 
which ICP0∆RING protein accumulated were indeed microtubule bundles.  This 
finding was also consistent with our prior observation that ICP0+GFP-105-containing 
bodies rapidly dispersed upon homogenization in ice-cold buffer; a condition 
known to cause depolymerization of microtubules (97). 
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Figure 15 
ICP0∆RING accumulates in linear structures that are nocodazole-sensitive. 
Vero cells were inoculated with 5 pfu per cell of HSV-1 0ΔRING in the presence 
of 200 μM cycloheximide from -0.5 to 10 hours p.i., and were released into 
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medium containing no drugs.  At 4 hours post-release, a representative field of 
view was chosen, and cells were treated with (A) vehicle or (B) 10 μg/ml 
nocodazole.  Between 4.0 and 4.5 hours after cycloheximide release, time-lapse 
photographs were captured at 10-minute intervals.  White asterisks denote cells 
in which ICP0∆RING was observed in a continuous, linear pattern encircling the 
nucleus of HSV-1 infected cells.  Scale bar = 10 µm. 
 
3.2.6. ICP0 is necessary for efficient dispersal of microtubules in HSV-1 
infected cells 
It is well established that the host cell microtubule network is disrupted 
during the course of HSV-1 infection (55, 98, 99).  However, it is unclear what 
process triggers microtubule reorganization in HSV-1 infected cells.  We 
questioned whether this event might be ICP0-dependent.   To test this 
hypothesis, α-tubulin and ICP0 staining were compared in Vero cells that were 
uninfected (UI) or were inoculated with HSV-1 KOS, HSV-1 0+GFP105, or an 
ICP0- null virus, HSV-1 0-GFP.  Cells were inoculated with 5 pfu per cell of each 
virus in the presence of cycloheximide for 10 hours to allow high and equivalent 
levels of ICP0+ and ICP0- mRNAs to accumulate (39).  At 1 and 4 hours post-
release, a normal distribution of α-tubulin staining was noted in uninfected Vero 
cells; specifically, microtubules radiated from the microtubule-organizing center 
on one side of the nucleus (Fig. 16A).  At 1 hour post-release, ICP0 and 
ICP0+GFP-105 were observed in the nuclei of cells infected with HSV-1 KOS and 
0+GFP105 (Fig. 16A).  Importantly, α-tubulin staining was always normal when 
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ICP0 or ICP0+GFP-105 were confined to the nucleus (Fig. 16A).  However, at 4 
hours post-release, ICP0 and ICP0+GFP-105 had translocated to the cytoplasm and 
this event coincided with dispersal of microtubules in KOS- and 0+GFP105-
infected cells, respectively (Fig. 16B).  Specifically, microtubule-organizing 
centers were no longer discernible, and α-tubulin was dispersed into globular 
bodies that co-localized with ICP0 or ICP0+GFP-105 (Fig. 16B).  In contrast, at 1 
and 4 hours post-release, cells inoculated with HSV-1 0-GFP retained an intact 
microtubule network that radiated from a perinuclear microtubule-organizing 
center (Fig. 16A, 16B).  Likewise, at 6 and 8 hours post-release, microtubule 
networks remained intact in HSV-1 0-GFP-infected cells (not shown).  Therefore, 
synthesis of ICP0 appeared to be necessary for the efficient dismantling of 
microtubule networks that normally occurs in HSV-1 infected cells (55).  
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Figure 16 
ICP0 is necessary for the dissolution of microtubule networks  
in HSV-1 infected cells. 
Vero cells were uninfected or were inoculated with 5 pfu per cell of HSV-1 strain 
KOS, HSV-1 0+GFP105, or HSV-1 0-GFP in the presence of 200 μM cycloheximide 
from -0.5 to 10 hours p.i., and were released into medium containing no drugs 
until the time of fixation.  At (A) 1 hour post-release or (B) 4 hours post-release, 
uninfected and KOS-infected cells were fixed and stained with antibodies against 
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α-tubulin (rabbit IgG) and ICP0 (mAb H1083).  HSV-1 0+GFP105 or 0-GFP-
infected cells were fixed and stained for α-tubulin, and ICP0+GFP-105 and ICP0-GFP 
proteins were visualized using their GFP fluorophores.  Nuclei were 
counterstained with the DNA-binding dye Hoechst 33342.  Scale bar = 10 µm. 
 
3.2.7. ICP0 is sufficient to dismantle microtubule networks in transfected 
cells 
The HSV-1 proteins US11 (100), UL34 (101), VP26 (102) and VP22 (56) 
interact with host cell microtubules.  Thus, ICP0 might be one of many HSV 
proteins that is required to disperse the intracellular ‘freeway system’ that is the 
cell’s microtubule network (103).  Alternatively, synthesis of ICP0 alone might be 
sufficient to disperse cellular microtubules.  To differentiate between these 
possibilities, Vero cells were transfected with pICP0, p0+GFP105, or p0ΔRING to 
determine if synthesis of ICP0 proteins affected the subcellular distribution of α-
tubulin, one of the principal structural subunits of the hollow, polymeric tubes 
known as microtubules (104). 
A normal distribution of α-tubulin staining was noted in mock-transfected 
Vero cells at 12 and 24 hours post-transfection.  Specifically, microtubules 
radiated from the organizing center on one side of the nucleus, and α-tubulin 
staining was not observed in the nuclei of mock-transfected Vero cells (Fig. 17A, 
17B).  Consistent with prior results (Fig. 10A-10C), wild-type ICP0 and ICP0+GFP-
105 were observed in the nuclei of cells transfected with pICP0 and p0+GFP105 at 
12 hours post-transfection (Fig. 17A).  At this early time, a normal distribution of 
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α-tubulin staining was noted in the cytoplasm, but to our surprise significant 
amounts of α-tubulin were present in the nuclei and co-localized with wild-type 
ICP0 and ICP0+GFP-105 (Fig. 17A).  Control staining with individual antibodies 
verified that the appearance of co-localization was not an unintended 
consequence of bleedover between the red and green channels (not shown).  In 
cells transfected with p0ΔRING, the ICP0∆RING protein was also observed in the 
nuclei of cells at 12 hours post-transfection, and a normal distribution of α-tubulin 
staining was noted in the cytoplasm.  However, large amounts of α-tubulin were 
present in the nuclei of transfected cells, and α-tubulin co-localized with the 
ICP0∆RING protein (Fig. 17A). 
At 24 hours post-transfection, wild-type ICP0 and ICP0+GFP-105 were 
observed in the nuclei and cytoplasm of cells transfected with pICP0 and 
p0+GFP105, respectively (Fig. 17B).  Translocation of ICP0 or ICP0+GFP-105 to the 
cytoplasm consistently correlated with 1. dissolution of the host cell microtubule-
organizing center and microtubule network, and 2. co-localization of α-tubulin 
with ICP0 or ICP0+GFP-105 in small, globular bodies in the cytoplasm (Fig. 17B).  
Likewise, 24 hours after transfection with p0ΔRING, ICP0∆RING protein co-
localized with α-tubulin in elongated microtubule bundles (Fig. 17).  Therefore, 
synthesis of the ICP0ΔRING protein was sufficient to trigger bundling, but not 
dispersal of microtubules.  In contrast, wild-type ICP0 was sufficient to trigger a 
complete dispersal of host cell microtubules. 
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Figure 17 
ICP0 is sufficient to trigger the dissolution  
of host cell microtubule networks. 
Vero cells were mock-transfected or were transfected with a VP16-expressing 
plasmid and pICP0, p0+GFP105, or p0∆RING.  At (A) 12 hours post-transfection or 
(B) 24 hours post-transfection, mock- and pICP0-transfected cells were fixed and 
stained with antibodies against α-tubulin (rabbit IgG) and ICP0 (mAb H1083).  
Cells transfected with p0+GFP105 or p0ΔRING were fixed and stained to visualize 
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α-tubulin, and the ICP0∆RING and ICP0+GFP-105 proteins were visualized using their 
GFP fluorophores.   Scale bar = 10 µm. 
 
3.2.8. ICP0 translocation and microtubule dispersal in a single HSV-1 
plaque 
High MOIs and cycloheximide-release experiments allowed robust 
visualization of ICP0 and co-localization of ICP0 with microtubule breakdown 
products.  These tests left unaddressed the question of whether or not ICP0 
actually translocates and/or dismantles microtubule networks during the normal 
progression of HSV-1 infection.  To address this issue, Vero cells were 
inoculated with wild-type virus at an MOI of 0.0001 pfu per cell, and the 
distribution of ICP0 and α-tubulin was analyzed in isolated HSV-1 plaques at 40 
hours p.i.  A single, representative plaque is considered to illustrate our findings 
(Fig. 18). 
With the enhanced sensitivity of immunofluorescent staining (versus direct 
imaging of GFP fluorescence, Fig. 10), low levels of ICP0 were detectable in the 
nuclei of cells at the outermost, advancing edge of HSV-1 plaques (• symbols, 
Fig. 18A).  In those HSV-1 infected cells in which ICP0 was observed solely in 
the nucleus, the perinuclear pattern of microtubule staining remained normal (• 
symbols, Fig. 18B).  Behind this advancing front, a second row of HSV-1 infected 
cells was observed in which ICP0 was far more abundant and predominantly 
localized to the cytoplasm of HSV-1 infected cells (X symbols, Fig. 18A).  When 
ICP0 accumulated in the cytoplasm of HSV-1 infected cells, gross reorganization 
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of the cellular microtubule network was observed (X symbols, Fig. 18B).  
Moreover, α-tubulin was frequently observed reorganized into linear structures or 
globular bodies that co-localized with wild-type ICP0 (white arrows, Fig. 18).  
Therefore, we conclude that regardless of MOI, a nuclear-to-cytoplasmic 
translocation of ICP0 routinely occurs in HSV-1 infected cells, and the timing of 
ICP0’s translocation to the cytoplasm coincides with a massive reorganization of 
the host cell’s microtubule network. 
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Figure 18 
Translocation of ICP0 and disruption of host cell microtubules  
in a single HSV plaque. 
Vero cells were inoculated with wild-type HSV-1 KOS virus at an MOI of 0.0001 
pfu per cell, and cells were fixed and stained at 40 hours p.i. using antibodies 
against (A) ICP0 and (B) α-tubulin. Nuclei were counterstained with the DNA-
binding dye Hoechst 33342.  Cells in which ICP0 was observed solely in the 
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nucleus are denoted by a circle (•) to the right of the nucleus.  Cells in which 
ICP0 was prominent in the cytoplasm are denoted with an ‘X’ to the right of the 
nucleus.  White arrows denote cells in which α-tubulin was not only dispersed, 
but also co-localized with ICP0.  Scale bar = 10 µm. 
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CHAPTER 4: DISCUSSION 
 
At the beginning of the dissertation, I set out to address the questions 1) 
how is ICP0 gene regulated, and 2) what function does ICP0 assume during HSV 
infection.  Regarding to the first question, the results of our study suggest that 
ICP0 gene is differentially regulated by virus-encoded repressor ICP4 and virus-
encoded antirepressor ICP0, which hints herpesviruses might deploy 
bacteriophage λ-like strategy to regulate their genes.  Regarding to the second 
question, the results of our study show that ICP0 dismantles the microtubule 
networks of HSV-infected cells, which indicates ICP0 might play a previously 
unrecognized role in the cytoplasm, and suggests a general function of many 
other viral E3 ligases.  The specific discussion regarding each question is 
detailed below: 
 
4.1. GENE REGULATION OF ICP0 
 
4.1.1. Identification of an ICP0-antagonized repressor of HSV mRNA 
synthesis 
HSV routinely establishes latent infections in its human host.  During the 
latent phase of infection, most of the HSV genome is transcriptionally silent.  It is 
unclear how the HSV genome is silenced, but it is generally agreed that 
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synthesis of ICP0 destabilizes repression and thus triggers reactivation of mRNA 
synthesis from latent HSV genomes (10, 11, 105).  
The search for an ICP0-antagonized transcriptional repressor has led 
investigators to consider the possibility that PML and Sp100 (18), IRF-3 and IRF-
7 (26), and centromere proteins CENP-B and CENP-C (27, 28) may represent 
the repressors of the HSV genome that are antagonized by ICP0.  Although ICP0 
may alter the subcellular distribution, stability, or function of these proteins, there 
is no direct evidence that these proteins are capable of restricting mRNA 
synthesis from the HSV genome.  Likewise, it has been postulated that 
epigenetic silencing may be the ICP0-antagonized repressive mechanism that is 
capable of silencing the HSV genome (21, 53).  However, no specific histone 
deacetylase or histone mark has been associated with more than a 2-fold 
reduction in HSV mRNA synthesis (19, 20, 53, 106). 
Although an ICP0-antagonized repressor has not been identified, it would 
be reasonable to expect that the repressive entity: 1. should be necessary and 
sufficient to restrict the synthesis of one or more HSV mRNAs; 2. should be 
unable to silence HSV mRNA synthesis when ICP0 accumulates; and 3. may 
physically interact with ICP0.  The results of the current study establish that 
HSV’s major transcriptional regulator, ICP4, meets these criteria, and thus 
appears to be the first bona fide ICP0-antagonized repressor of HSV mRNA 
synthesis. 
The results clarify that ICP4 is capable of silencing mRNA synthesis from 
the ICP0 gene when ICP0 fails to accumulate.  At low MOIs, HSV ICP0- viruses 
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establish quiescent infections in 99% of infected cells (12, 13).  Intriguingly, ICP4 
accumulates to detectable levels in >85% of cells that become quiescently 
infected with HSV ICP0- viruses (107).  Thus, further studies will be required to 
determine if 1. ICP4 often accumulates in the absence of ICP0 in HSV 
quiescently infected cells (108-110), and if 2. ICP4 may contribute to quiescent 
HSV infections by restricting mRNA synthesis from HSV IE genes. 
 
4.1.2. Differential regulation of ICP0 mRNA synthesis in HSV-infected cells 
  There is anecdotal evidence that the ICP0 gene is differentially regulated 
in HSV-infected cells, but it remains unclear how such regulation is achieved.  
The HSV latency-associated transcripts (LATs) have been discussed for their 
potential to repress ICP0 gene expression (111, 112).  Likewise, VP16’s capacity 
to function as a transactivator of IE genes has been considered as a potential 
target of differential regulation (113-115).  However, it remains unclear that LATs 
or VP16 are sufficient to explain how the ICP0 gene is regulated. 
The ICP4-binding site in the ICP0 promoter was identified 20 years ago as 
a potential means by which ICP4 might regulate ICP0 mRNA synthesis (89).  
When studied in the context of HSV ICP0+ viruses, some investigators concluded 
that ICP4’s effect on ICP0 gene expression was negligible (37).  Other 
investigators noted that ICP4 produced a modest decrease in ICP0 mRNA levels 
in the context of  ICP0+ viruses (38), but ICP4’s full potential to silence ICP0 
gene expression went unrecognized. 
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The current study demonstrates that the ICP0 gene is differentially 
regulated by three HSV proteins, VP16, ICP4, and ICP0, whose relationship to 
one another is not resolved.  Functionally, the results suggest that VP16 and 
ICP4 ‘push’ ICP0 mRNA synthesis in opposite directions, and accumulation of 
ICP0 dictates which way this equilibrium will tilt.  When ICP0 fails to accumulate, 
ICP4 is capable of silencing ICP0 mRNA synthesis despite VP16 in the tegument 
of virions (Figure 3-6; ICP0- treatments).  When formation of the de novo 
repressor is blocked with cycloheximide, VP16’s full capacity to transactivate the 
HSV-1 ICP0 gene is revealed (Figure 5).  If ICP0 accumulates, ICP4 no longer 
represses ICP0 mRNA synthesis (Figure 3-6; ICP0+ treatments).  These findings 
suggest that a hierarchy exists in the HSV regulatory scheme in which i. ICP0-
dependent antirepression of the ICP0 gene is dominant over ii. ICP4-dependent 
repression of the ICP0 gene, which is dominant over iii. VP16-dependent 
induction of the ICP0 gene.   Therefore, while VP16 induces transcription of both 
the ICP4 and ICP0 genes, the opposing processes of ICP4-dependent 
repression and ICP0-dependent antirepression appear to dictate whether the 
ICP0 gene will remain ON or OFF in HSV-infected cells (Figure 3B). 
 
4.1.3. ICP0 as a regulatory subunit of ICP4: a missing lynchpin in HSV gene 
regulation? 
The 1298-amino-acid ICP4 protein functions as an essential activator that 
recruits cellular TATA-binding protein complexes to HSV genomes, and thus 
stimulates mRNA synthesis from HSV E and L genes (88).  ICP4 also possesses 
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a second activity as a repressor of HSV IE genes, which requires the binding of 
350 kDa ICP4 homodimers to consensus ATCGTC sequences (116, 117).  To 
date, it remains unclear how the balance between ICP4’s opposing 
transcriptional repressor versus activator functions is controlled.  
Since the discovery that ICP0 re-organizes PML nuclear bodies (30), ICP4 
and ICP0 have been predominantly studied in isolation from one another.  
However, ICP0 was initially discovered as a factor that stimulated a 20-fold 
increase in ICP4-dependent mRNA synthesis from HSV E and L promoters (9).  
The results of the current study establish that ICP0 and ICP4 participate in a 
robust physical interaction in HSV-infected cells (Figure 9).  We postulate that 
ICP0’s physical interaction with ICP4 is likely regulatory in nature, and hence 
may be relevant in explaining how ICP0 potentiates ICP4-dependent E and L 
mRNA synthesis (8, 9), as well as how ICP0 antagonizes ICP4-dependent 
repression of ICP0 mRNA synthesis (Figure 3 - 5).   Therefore, we propose that 
the accumulation of ICP0 in HSV-infected cells (or lack thereof) may dictate 
whether ICP4 functions predominantly as an activator, or a repressor, of HSV 
mRNA synthesis.  Further studies will be required to test the validity of this 
important hypothesis. 
 
4.1.4. How does ICP0 antagonize ICP4-dependent repression? 
What specific protein-DNA complexes explain how ICP0 antagonizes 
ICP4-dependent silencing of the ICP0 gene?  The mechanisms that underlie the 
phenomenon documented in this study are unknown, and further study will be 
84 
 
required to differentiate between scores of possibilities.  In an effort to illustrate 
this point, we present two distinct molecular models that are compatible with the 
results of the current study. 
The first model, the ICP0-ICP4 Interference Model, is the most intuitively 
obvious interpretation and may reflect the mental model that many readers have 
invoked up to this point in the manuscript to make sense of the results.  Under an 
ICP0-ICP4 Interference Model, it could be predicted that 1. ICP4 binding to HSV 
dsDNA serves the sole purpose of repressing mRNA synthesis from adjacent 
HSV genes, and that 2. ICP0 blocks ICP4’s capacity to bind dsDNA, and thus 
ICP0 blocks ICP4-dependent repression of the HSV ICP0 gene.  However, 
synthesis of ICP4 is required for synthesis of viral E and L mRNAs, and 
mutations that disrupt ICP4’s DNA-binding domain also render HSV incapable of 
synthesizing its ~70 E and L mRNAs that are required for HSV replication (71, 
83, 118).  Therefore, it is difficult to envision how an ICP0-based activity that 
dislodges ICP4 from dsDNA would help explain how ICP0 potentiates ICP4-
dependent synthesis of HSV E and L mRNAs (8, 9). 
An ICP0-ICP4 Synergy Model is less intuitively obvious, but is more 
consistent with ICP0’s capacity to enhance ICP4-dependent synthesis of HSV E 
and L mRNAs.  Under this latter model, it may be envisioned that 1. the 
functional purpose of ICP4 and the >50 ICP4-binding sites that span the HSV 
genome is to allow ICP4 to form a histone-like scaffold that coats HSV genomes; 
2. the 1298 amino-acid ICP4 protein possesses numerous domains that allow 
ICP4 to interact with cellular proteins (119, 120) and viral proteins (Figure 9) 
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which influence whether ICP4 stimulates or represses mRNA synthesis from the 
underlying HSV DNA; and 3. the nature of ICP0’s interaction with ICP4 relates to 
potentiating ICP4-dependent activation of mRNA synthesis from HSV DNA.  
Clearly, further investigation will be required to determine if the specific protein-
DNA interactions that occur in HSV-infected cells are consistent with an ICP0-
ICP4 Synergy Model of HSV gene regulation. 
 
4.1.5. Repression-antirepression model of ICP0 gene regulation: 
evolutionarily conserved gene regulation scheme? 
The herpesviruses and temperate bacteriophage are large dsDNA viruses 
that share the capacity to alternate between productive and silent infections.  
Many similarities have emerged in the mechanisms that herpesviruses and the 
tailed bacteriophage employ to replicate and encapsulate their large dsDNA 
genomes (121-124).  Such observations point to a common evolutionary 
ancestry between these two ancient families of viruses (125, 126).  We conclude 
that the results of the current study appear to add to this growing list of 
inexplicable similarities. 
The parallel capacity of HSV and bacteriophage λ to alternate between 
productive and silent infections may not be a coincidence.  Rather, both viruses 
may control the onset of viral replication through a system of repression and 
antirepression of a few IE proteins whose accumulation, or lack thereof, dictates 
the probability of replication.  In λ phage, the ‘decision’ between productive 
versus silent infections hinges upon whether the λ cro antirepressor gene is 
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expressed or repressed (127-129).  Thus, important questions follow from the 
observation that HSV encodes its own transcriptional repressor function, 
embedded in ICP4, which is capable of silencing the HSV antirepressor gene that 
encodes ICP0.  Further study will be required to determine if, in fact, repression-
antirepression of the ICP0 gene is relevant to the natural process by which HSV 
‘decides’ whether a given infection will be productive or silent. 
 
4.2. FUNCTION OF ICP0 
 
4.2.1. ICP0 serves distinct roles in the nucleus and cytoplasm of HSV-
infected cells 
Studies of ICP0 have focused on the protein’s role in the nucleus (17, 27, 
53, 54).  Cytoplasmic ICP0 has been repeatedly observed (48-52), but its 
significance remains obscure for two reasons.  First, the kinetics of ICP0’s 
nuclear-to-cytoplasmic translocation has been poorly defined.  Thus, it has not 
been apparent that ICP0’s function in the cytoplasm is kinetically delayed and is 
only manifest once ICP0 fulfills its IE function in the nucleus (8, 9, 39).  Second, 
the role that ICP0 fulfills in the cytoplasm of HSV-infected cells has not been 
clearly articulated.  The results of the current study address these gaps in 
knowledge. 
The results of the current study demonstrate that once E proteins 
accumulate, ICP0 translocates to the cytoplasm (Fig. 12) and there dismantles 
the host cell’s microtubule network.  Five observations support this conclusion: 1. 
87 
 
Microtubule dispersal is ICP0-dependent in HSV-infected cells (Fig. 16); 2. 
Synthesis of ICP0 is sufficient to trigger microtubule dispersal (Fig. 17); 3. 
Dispersal of microtubule bundles is dependent upon ICP0’s RING finger domain 
(Fig. 14); 4. The timing of microtubule dispersal coincides with ICP0’s 
translocation to the cytoplasm (Fig. 16); and 5. α-tubulin+ breakdown products 
co-localize with ICP0 (Fig. 16). 
 
4.2.2. GFP-tagged ICP0 yields new insights into the biology of ICP0 
HSV-1 viruses that encoded chimeric ICP0+GFP proteins formed plaques 
with ~66% efficiency relative to wild-type HSV-1 (Fig. 1E).  Using this new tool, 
we were able to observe GFP-tagged ICP0 in the act of bundling and/or 
dispersing microtubules in the cytoplasm of HSV-infected cells.  These findings 
would be difficult to ascertain from analysis of fixed cells because ICP0’s 
cytoplasmic pattern is pleomorphic in HSV-infected cells.  However, direct 
observation of a single HSV-infected cell in real time reveals the fluid process by 
which GFP-tagged ICP0 triggers the disassembly of subcellular structures, which 
proved to be part of the microtubule network (Figs. 13 and 14; Table 3). 
 
4.2.3. Virus-induced reorganization of host cell microtubules 
Many animal and plant viruses use host cell microtubule networks during 
their replication cycle (59-61).  For example, movement protein of tobacco 
mosaic virus (130) and transmission factor of cauliflower mosaic virus (131) 
modify microtubules in plant cells.  The human immunodeficiency virus Rev 
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protein forms dimers that bind microtubule ends, and inhibit their polymerization 
(132).  The 3C protease of foot-and-mouth disease virus cleaves microtubule-
associated protein 4, and thus excludes microtubules from cytoplasmic 
replication compartments (58, 133).  Expression of Epstein-Barr virus’s LMP-1 
protein or SV40’s large T antigen causes formation of aberrant microtubule 
structures via the respective modulation of microtubule-stabilizing proteins 
RASSF1 A (134) and TACC2 (59).  While many viruses modify the microtubule 
network during their replication cycles, the functional significance of these 
interactions is often unclear.  Thus, there is no clear virological precedent that 
explains why HSV should encode a protein, ICP0, that dismantles the 
microtubule network. 
 
4.2.4. ICP0:  a viral E3 ligase that orchestrates microtubule disassembly 
The current study provides the first example of a viral E3 ligase that 
triggers microtubule disassembly.  Most of the ~20 α-herpesviruses whose 
genomes have been sequenced encode RING-finger E3 ligases (65).  These 
include varicella-zoster virus (135), pseudorabies virus (136), and channel catfish 
virus (137).  Based on our results, we predict that each of these RING-finger E3 
ligases will also 1. fulfill dual roles in the nucleus and cytoplasm of virus-infected 
cells, and 2. will dismantle microtubule networks upon their translocation to the 
cytoplasm.  Clearly, further testing is required to test the validity of this prediction. 
The α-herpesviruses are not alone in their use of E3 ligases as regulatory 
molecules.  The Rta protein of Kaposi’s sarcoma herpesvirus possesses intrinsic 
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E3 ligase activity despite the absence of a canonical RING finger domain (138).  
Intriguingly, both ICP0 and Rta E3 ligases are sufficient to trigger reactivation of 
latent herpesviral infections (10, 139).  Most viruses are too small to encode their 
own E3 ligases.  Thus, smaller RNA and DNA viruses exploit ubiquitination as a 
regulatory mechanism by encoding adapter proteins such as adenovirus E1b, 
papillomavirus E6 and E7, or paramyxovirus V proteins that redirect cellular E3 
ligases to substrates that benefit the virus (138, 140-143).  It will be of interest to 
determine in coming years if any of these other viral E3 ligases reorganize host 
cell microtubule networks.  
Many cellular E3 ligases play a prominent role in coordinating the complex 
events that transpire during mitosis, and which include disassembly of the 
microtubule network (63).  For example, cullin 3 is an E3 ligase that regulates the 
activity of a microtubule-severing protein known as katanin (i.e., ‘sword’ in 
Japanese; Ref. (63, 64, 144)).  Given the propensity of viruses to steal useful 
cellular functions (138, 145), our results raise the possibility that ICP0 may be 
derived from one of the many cellular E3 ligases that influences cell-cycle 
progression via regulating the disassembly and reassembly of microtubule 
networks (63).  Specifically, our results imply that ICP0 possesses a mitosis-
related regulatory activity that is manifest upon its translocation to the cytoplasm.  
Further investigation will be required to test the validity of this important 
hypothesis. 
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4.2.5. Is α-tubulin a substrate of ICP0’s E3 ligase activity?   
The discovery of ICP0’s E3 ligase activity by Everett and colleagues (15, 
16) arose from a need to explain why PML nuclear bodies were dispersed shortly 
after ICP0 arrived in these sub-nuclear structures (30, 42, 43).  Although it 
seemed likely that PML would prove to be a direct substrate of ICP0’s E3 ligase 
activity, the development of a robust in vitro assay for ICP0’s E3 ligase activity 
demonstrated that this was not the case (15, 45). 
It is possible that α-tubulin may be a direct substrate of ICP0’s E3 ligase 
activity, but the history of ICP0 research suggests that such speculation is 
premature.  What should be considered, however, is the extraordinarily robust 
co-localization of α-tubulin and ICP0.  For example, in transfected cells, large 
amounts of α-tubulin co-localized with ICP0 in the nucleus, which is not normally 
observed in uninfected cells (Fig. 17).  These results suggest that newly 
synthesized ICP0 may be tethered to α-tubulin so rapidly in the cytoplasm that 
the ICP0-containing complexes that are imported into the nucleus may also 
contain sizable amounts of α-tubulin.  Moreover, ICP0 co-localized with 
dispersed α-tubulin+ structures for hours after disassembly of the microtubule 
network (Fig. 14, 16, 17).  In contrast, ICP0’s nuclear interactions with PML (30, 
43) and ICP4 (39, 80) appear to be far more transient in nature.  Clearly, further 
work is needed to define how ICP0’s E3 ligase activity triggers microtubule 
disassembly in host cells, and to define why ICP0’s interaction with α-tubulin 
appears to be so much more stable than any other cellular protein identified to 
date. 
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4.2.6. ICP0-induced disassembly of microtubules versus G2/M cell cycle 
arrest 
Synthesis of ICP0 causes dividing cells to arrest in the G2/M phase of the 
cell cycle (27, 46, 47).  Two explanations for this phenomenon have been offered 
including ICP0-induced degradation of centromere protein-C (27), and ICP0-
induced activation of a DNA damage response pathway (146).  The current study 
suggests a third possibility; ICP0-induced disassembly of microtubules produces 
the same type of G2/M arrest that is caused by nocodazole (147). 
The rationale for this proposal is explained.  The microtubule bundles in 
which ICP0ΔRING stably accumulated (Figs. 13 and 14) were rapidly destabilized 
upon treatment with nocodazole (Fig. 15).  The resulting ICP0ΔRING+ globular 
bodies that were dispersed upon nocodazole treatment were α-tubulin+, and 
were indistinguishable in appearance from the ICP0+ α-tubulin+ globular bodies 
that formed in HSV-infected cells (Fig. 18).  Thus, our results suggest that, like 
nocodazole, ICP0 triggers the rapid disassembly of microtubules. 
Nocodazole causes cells to arrest in the G2/M phase of the cell cycle by 
blocking mitotic spindle formation, which is needed to align chromosomes on the 
metaphase plate prior to their segregation into daughter cells (147).  Thus, 
nocodazole treatment causes cell division to arrest in prometaphase (148).  
Likewise, synthesis of ICP0 has nocodazole-like effects on cell division (46, 47).  
Specifically, chromosome condensation occurs normally in cells treated with 
ICP0-expressing viruses (27) or nocodazole (148), but in both cases the 
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condensed chromosomes fail to align on metaphase plates (27, 148).  Further 
work will be required to test the validity of this interpretation, and determine if 
ICP0-induced disassembly of microtubules explains why synthesis of ICP0 
causes cell division to stall during mitosis. 
 
4.2.7. Functional consequences of host cell microtubule networks 
disruption by herpesviruses 
In recent years, the list of viruses that interact with cellular microtubules 
has grown in length, but the general significance of the phenomenon remains 
unclear.  Herpesviruses rely on microtubules as a ‘conveyor belt’ to carry their 
incoming virions from the cell membrane to the nuclear pore (103, 149).  
Therefore, it is conceivable that disruption of this conveyor belt may be critical for 
virion egress, such that newly formed herpesvirus virions may flow efficiently in 
the reverse direction, from the nucleus back to the cell membrane.  Of course, 
many other possibilities exist and warrant equal consideration.  For example, 
ICP0-induced disruption of microtubules may elicit massive changes in the cell’s 
metabolism that may be needed late in infection to produce the vast quantities of 
energy and protein required during the logarithmic phase of virion synthesis 
(150).  Likewise, if microtubule disassembly is linked to ICP0’s capacity to disrupt 
mitosis, it is conceivable that microtubule disassembly could provide signals that 
would cause the host cell to respond by producing a whole suite of DNA repair 
enzymes that might be critical for the synthesis, recombination, and/or packaging 
of HSV DNA (54).  Whatever the correct explanation proves to be, it should 
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account for the fact that modulation of microtubules is not HSV-specific, but 
rather is likely critical to the herpesviruses as a group.  In light of these 
considerations, it will be of particular interest to determine in coming years if viral 
E3 ligase-dependent dismantling of microtubule networks is unique to the 
herpesviruses, or rather is paralleled in the replication strategies of other plant 
and animal viruses (151-153).  
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CHAPTER 5: CONCLUSION 
 
Two questions were posed at the beginning of the dissertation: 1) how is 
ICP0 gene regulated, and 2) what function does ICP0 assumes.  Regarding to 
the first question, we found that ICP0 gene is subject to potent ICP4-dependent 
repression immediately following HSV infection.  ICP0 physically interacts with 
ICP4, and antagonizes ICP4’s repressive activity.  Therefore, we conclude that 
ICP0 gene is differentially regulated by virus-encoded repressor ICP4 and virus-
encoded antirepressor ICP0.  The balance between ICP0 and ICP4 likely 
determines the “ON” and “OFF” of ICP0 gene, which contributes to the lytic 
versus latent decision of HSV. 
Our pursuit of the second question began as we unexpectedly found that 
ICP0 is predominantly localized to the cytoplasm of HSV-infected cells.  Further 
investigations showed that ICP0 translocates from nucleus to cytoplasm during 
the early phase of infection, where it bundles and disperses host cell microtubule 
networks.  The RING-finger domain, which confers E3 ligase activity to ICP0, is 
required to the microtubule-dispersing activity, not the microtubule-bundling 
activity.  Our study represents the first report of a virus-encoded E3 ligase that 
disrupts microtubule networks of the host cell.  Since nearly all the α-
herpesviruses encode an E3 ligase, our findings hint a general function of virus-
encoded E3 ligase, which is to dismantle microtubule networks. 
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Finally, we conclude that ICP0 assume dual functions during the life cycle of 
HSV: 1) In the very early stage of HSV replication, ICP0 is an exclusively nuclear 
protein, which promotes HSV gene expression through antagonizing ICP4’s 
repressive activity; 2) In the very late stage of HSV replication, ICP0 translocates 
to the cytoplasm, where it dismantles host cell microtubule networks, which may 
facilitate viral spread. 
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